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Abstract(
Although Staphylococcus aureus is exposed to antimicrobial fatty acids on the skin, in
nasal secretions and in abscesses, specific mechanisms for regulating gene expression and
intrinsic resistance in response to these fatty acids have not been reported. Through in
vitro selection for increased resistance of S. aureus to linoleic acid, I identified fatty acid
resistant clone FAR7, where a single nucleotide polymorphism caused a His121Tyr
substitution in an uncharacterized member of the TetR family of transcriptional
regulators, which is divergently transcribed from a gene encoding a member of the
resistance-nodulation-division superfamily of multi-drug efflux pumps. I named these
genes farE and farR, for regulator and effector of fatty acid resistance, respectively. S.
aureusΔfarER exhibited loss of inducible resistance to linoleic acid, and although FarR is
a TetR family regulator which typically repress expression of a divergent gene, I found
that FarR is needed to induce farE. Compared to wild type S. aureus, FAR7 exhibited
increased expression of farR and farE under non-inducing conditions, and a significantly
higher induced level of farE. Electrophoretic mobility shift assays revealed a FarR
binding site in the farER intergenic segment, that overlaps with the +1 transcription start
site of farR as determined by 5"-RACE. The variant FarR7 produced by S. aureus FAR7
failed to bind to this operator site, and nucleotide substitutions within the operator
abolished binding of native FarR. Conversely, FarR and FarR7 bound equally well to a
second operator site upstream of the predicted farE promoter. Therefore, like other TetR
regulators, FarR represses its own expression, and a His121Tyr substitution in FarR causes
a loss of auto-repression and increases expression of both farR and farE. My data reports
the first description of a specific mechanism of inducible resistance to antimicrobial fatty
acids in a Gram-positive pathogen and defines a new paradigm for regulation of a
divergently transcribed gene by a TetR family regulator.

Keywords
Antimicrobial fatty acids, efflux pumps, TetR family regulator, inducible resistance,
Staphylococcus aureus.
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Chapter(1((

1(

Introduction(

(

1

1.1( Staphylococcus,aureus,Overview(
Staphyloccous aureus is a Gram-positive bacterium from the Firmicutes phylum that is
considered

as

a

pathobiont.

It

colonizes

~30%

of

the

human

population

asymptomatically, and thus is a part of the resident microbiota, but also a pathogen
proficient in causing diverse cutaneous and systemic infections of ranging severity (1). In
his attempt to examine the underlying cause of blood-poisoning in 1881, Alexander
Ogston observed micrococci with a spherical outline that stained a uniformly deep violet
and grouped into clusters. He examined a series of chronic and acute abscesses and found
them to contain micrococci mingled with pus. When these micrococci were injected into
subcutaneous tissue of test animals, they were capable of proliferating, forming
inflammatory knots, invading the tissue, and disseminating into the blood stream. In
1882, these micrococci were named Staphylococcus (2–4). Since this first description as a
causative agent of human infection, S. aureus has been and continues to be a leading
cause of human infectious morbidity and mortality. Over the past few decades,
community-acquired methicillin-resistant S. aureus (CA-MRSA) strains have become a
significant disease burden on healthcare systems worldwide (5). These strains display
hyper-virulence and effective host-to-host transmission at a relatively minor fitness cost,
posing a serious threat to public health systems (6). In fact, MRSA accounts for 78% of
the skin and soft tissue infections presented to emergency departments in eleven cities in
the United States; 98% of these infections being caused by the community-acquired
MRSA (CA-MRSA) clone USA300, which is the strain of choice in our studies (7).

1.2( Emergence(of(Methicillin0Resistant(Community0
acquired(Staphylococcus,aureus,,
Prior to the debut of penicillin, the mortality rate of S. aureus bacteremia patients was as
high as 80% (8), and as early as two short years after the introduction of the antibiotics,
resistant strains of S. aureus resistant began to emerge (9). Penicillin-resistant S. aureus
isolates, owing to the production of β-lactamases, were reported in the healthcare and
community settings in the 1950s (10). Subsequently, methicillin use was introduced into
clinical practice, but the resilient S. aureus developed methicillin resistance rapidly (11,
12). MRSA infections represent a significant burden on the healthcare system, and are
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found to be associated with increased length of hospitalization (13, 14). In a survey of
staphylococcal infections across the United States, Canada, Latin America, Europe, and
the Western Pacific region, MRSA was found to be the most prevalent cause of
bacteremia, pneumonia, and skin and soft tissue infections (15). For decades, MRSA
infections were mostly limited to healthcare settings such as hospitals and nursing homes;
however, in the late 1990s community-acquired isolates were first reported. The
prevalent clinical presentations were mainly fatal necrotizing pneumonia, septicemia, and
pulmonary abscesses (16, 17). There were five CA-MRSA strains responsible for the
majority of staphylococcal disease worldwide; the Midwest Clone, the Southwest Pacific
Oceania Clone, the European Clone, the Pacific Clone, and the USA300 clone (18).
USA300 was named after the unique profile of its pulse-field gel electrophoresis (19).
This clone which has been responsible for severe disease outbreaks in the past (17, 20), is
currently the predominant strain of S. aureus in North America, and accounts for 98% of
infections presented to emergency departments (7, 21).

1.3( Staphylococcus,aureus,colonization(
S. aureus colonizes the skin and mucosal surfaces such as the nose and throat, as well as
the axillae, vagina, and perineum; however, the preferred site of colonization seems to be
the anterior nares (22–25). S. aureus binding to mucin is an important factor in the
organism’s ability to colonize the nasopharyngeal mucosal surfaces (26). Approximately
30% of the population are transient carriers, and 20% are persistent carriers of S. aureus
in the anterior nares (27). Moreover, there is a greater possibility of recovering S. aureus
from other body sites among these carriers compared to non-carriers (1). In fact, selfinfection in carriers of S. aureus has been reported as early as in the late 1950s. Williams
et al. in 1959 noticed that infectious staphylococcal strains were normally the same
strains that colonized the nares in the same individual (28). Additionally, Von Eiff et al.
in 2001 reported that 82% of their sampled bacteremia patients displayed diseases caused
by staphylococcal strains of endogenous origin (29). Strains obtained from the nares of
these patients were identical to those in the blood up to 14 months later (28, 29).
Another target of S. aureus colonization, and subsequent infection, is the skin that
represents the residence of multiple microorganisms including bacteria, viruses, fungi and
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even mites (30–32). The microbiome that makes up the skin is more variable over time
when compared to that of the gut and mouth (33). The skin microbiome can vary with
topography, thickness, and frequency of cutaneous appendages such as sweat, sebaceous
glands, and hair follicles (34). Sebum, for instance, is a lipid-rich antibacterial coating
that lubricates and protects the skin. It is secreted from the sebaceous glands and
differentiated keratinocytes in the stratum corneum of the skin. These sebaceous glands
are associated with the hair follicles, and support anoxic conditions allowing for selection
of facultative anaerobic microorganisms. Studies have shown that Propionibacterium
acnes, for instance, can grow in sebaceous glands and secrete lipases that break down
sebum lipids (35). Sebum triglycerides undergo enzymatic hydrolysis by P. acnes
resulting in the release of free fatty acids on the skin (36, 37). Additionally, hormone
production, life style choices such as occupation and antibiotic use, and the genetic
profile of the host also contribute to the variability of the skin microbiome (38–40).
Staphylococcal species are considered one of the most stable inhabitants of the skin (41).
They have developed mechanisms that enable them to inhabit moist skin
microenvironments, most likely by utilizing the urea component of sweat as a nitrogen
source (42). Breaching cutaneous immunity on the skin provides an opportunity for
pathobionts, like S. aureus, to establish infections. The introduction of foreign objects,
such as indwelling medical devices, also provide a niche for staphylococcal colonization.
Moreover, members of the resident skin microbiota might contribute to cutaneous
immunity, as was reported by Iwase et al. in which a subset of Staphylococcus
epidermidis strains evolved to produce an endopeptidase protein that cooperatively works
with the host's β-defensin 2 to impede S. aureus colonization and biofilm formation (43).

1.4( Staphylococcus,aureus(pathogenesis(and,clinical(
manifestation(
Although S. aureus is considered a normal constituent of the human microbiota, it is also
a highly successful opportunistic pathogen (1). Upon breach of cutaneous immunity, S.
aureus excels at epithelial adhesion, invasion, and subsequently immune evasion to
establish a successful infection. To accomplish pathogenesis, S. aureus employs a
collection of virulence determinants that can be divided into three categories: secreted
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enzymes; adhesion and immune evasion factors; and toxins. Secreted enzymes that are
associated with S. aureus adhesion and invasion include: glycerol ester hydrolases that
are involved in degradation of triacylglycerols; phosphphatidylinositol-specific lipase
(PtdIns-phospholipase C); and enolases that mediate binding to laminin (44–49).
Adhesion factors include a plethora of microbial surface proteins known collectively as
microbial surface components recognizing adhesive matrix molecules (MSCRAMMs)
(50). The acronym was first used in 1994 to describe microbial adhesins, such as
fibronectin-binding proteins A and B, collagen-binding adhesin, and S. aureus surface
protein G/S, that span the staphylococcal wall, and have exposed domains which
recognize host proteins such as fibronectin, fibrinogen, laminin, collagen, and heparin
associated polysaccharides with a high degree of specificity (50–59). Subsequently, S.
aureus is able to evade host immune defenses with factors such as staphylococcal protein
A which binds immunoglobulins to block phagocytosis, and toxins such as δ toxin which
is involved in neutrophil lysis and the lethal α toxin (60–70). A brief summary of S.
aureus virulence determinants and their functions is listed in Table 1.1
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Table 1.1 Summary of S. aureus virulence determinants.
Category

Secreted
enzymes

Determinant

Function

Reference

SspA (serine protease)

Cleaves fibronectinbinding protein as well
as cleaves the heavy
chains of all human
immunoglobulin
classes.

PtdIns-phospholipase
C

Phosphatidylinositolspecific lipase activity
that releases glycanPtdIns-anchored cell
surface proteins.

(45, 48)

Enolase

Mediates the binding
to laminin.

(45, 49)

glycerol ester
hydrolase

Involved in
degradation of
triacylglycerols, and
impede human
granulocyte function.

(44, 45)

(71–74)

Adhesion factors
Fibronectin-binding
proteins A and B

Bind fibronectin,
fibrinogen and elastin.

(51–54)

S. aureus surface
protein G and S

Binds to the
extracellular matrix.

(58, 59)

Collagen-binding
adhesin

Binds collagen I and
IV.

(55–57)

Elastin-binding protein

Binds to elastin.

(75, 76)

von Willebrand factor
binding protein

Binds von Willebrand
factor and fibrinogen.
Also binds and

(47)
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activates prothrombin.
Adhesion and
immune
evasion
factors

Extracellular
adherence protein

Binds to extracellular
matrix. Also displays
immunomodulatory
properties.

(77–81)

Extracellular matrix
protein-binding
protein

Binds to the
extracellular matrix.

(82)

Bone sialoproteinbinding protein

Binds bone
sialoprotein as well as
fibrinogen.

(83–85)

Iron-regulated surface
determinants A, B, C,
and H

IsdA binds to
fibrinogen, fibronectin
and transferrin. IsdB
binds hemoglobin and
hemin. IsdC binds
hemin. IsdH binds
haptoglobinhemoglobin complex.

(86–92)

Immune evasion factors

Staphylokinase

Involved in
plasminogen
activation and defensin
inactivation. Displays
anti-opsonic and
fibrinolytic properties.

(93–96)

Protein A

Binds
immunoglobulins,
tumor-necrosis factoralpha receptor 1 and
von Willebrand factor.

(61–63)

Staphylococcal
complement inhibitor

Acts on C3
convertases to inhibit
complement

(97)
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Toxins

Chemotaxis inhibitory
protein

Binds to C5a and
blocks chemotaxis

(98, 99)

Extracellular
fibrinogen-binding
protein

Binds fibrinogen as
well as complement
C3. Recruits plasmin
to degrade C3 and
C3b. Inactivates
complement.

(100–103)

Capsular
polysaccharides

Impede phagocytosis

(104–106)

Multiple peptide
resistance factor F

Modifies membrane
phosphatidylglycerol
with L-lysine.
Mediates resistance to
cationic antimicrobial
peptides and defensins
as well as evasion of
neutrophil killing.

(107, 108)

Antimicrobial peptide
sensing system

Two component
histidine kinase and
response regulator
system that is involved
in antimicrobial
peptides resistance.

(109, 110)

α toxin

Pore-forming
cytotoxin. Stimulates
inflammatory
cytokines.

(66–70)

β hemolysin

Cytotoxic action.

(111, 112)

δ toxin

Cytotoxicty and
membrane-damaging
properties as well as
induction of tumor
necrosis factor alpha

(64, 65)

8

production.
γ toxin

Hemolytic activity.

(113, 114)

Enterotoxins

Superantigen with
immunomodulatory
properties via potent T
cell activation.

(115, 116)

Toxic shock syndrome
toxin 1

Superantigen with
immunomodulatory
properties via potent T
cell activation.

(115, 117–119)

Leukocidins A, B, D,
E and M.

LukA/B have cytolytic
activity towards
macrophages and
neutrophils. Luk
D/E/M have
leukocidal activity.

(120–123)

Panton-Valentine
leukocidin

Pore-forming toxin
with cytolytic activity
towards macrophages
and neutrophils.

(124–127)
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S. aureus can cause mild skin and soft tissue infections as well as life-threatening
infections such as infective endocarditis, osteomyelitis, and sepsis. In the early 1990s,
these infections were primarily nosocomial, and spread rapidly in healthcare settings. In
one report, a single MRSA strain spread in two hospitals in British Colombia and
Manitoba within 6 weeks from the strain’s introduction from the Punjab (128). First
reports of CA-MRSA infections were documented in the United States in 1997, and since
then CA-MRSA strains have proven to be hyper-virulent especially those belonging to
the USA300 lineage (129). USA300 is particularly hyper-virulent for multiple reasons:
first, it carries a smaller staphylococcal cassette chromosome (SCCmec) than that
possessed by hospital-acquired strains, and thus has a relatively lower fitness cost (130);
second, it is notorious for causing destructive infections such as necrotizing pneumonia
due, in part, to the production of Panton-Valentine leucocidin (PVL) that causes
leukocyte destruction and tissue necrosis (16, 131); third, it has acquired the arginine
catabolic mobile element (ACME) from the skin commensal S. epidermidis which
encodes determinants of resistance and virulence that enhance pathogenesis (132).

1.5( Genetic(regulation(of(Staphylococcus,aureus,virulence(
In addition to the cell wall associated factors, enzymes, and toxins mentioned above, S.
aureus virulence is regulated extensively at the transcriptional level. This regulation is
rather complex and involves a combination of multiple sensory and regulatory systems.
The principal regulatory system in S. aureus is the accessory gene regulator, agr. The agr
locus contains four genes, agrBDCA, and RNAIII which is the effector molecule of this
global regulatory locus. The gene agrB encodes a membrane-associated protease that
alters the agrD-encoded prepropeptide. This alteration results in the production of the
small peptide molecule, which is the signal for membrane associated sensor kinase
encoded by agrC. The recognition of this signal then results in AgrC activating the
response regulator that is encoded by agrA, and this in turn upregulates RNAIII
expression. (133–135). RNAIII governs the regulation of an array of virulence
determinants, both at the transcriptional and translational levels. Additionally, there are
other two-component regulatory systems and global transcriptional regulators that work
with, and independent of, the agr system to govern the pleiotropic regulation of
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staphylococcal virulence. A brief summary of those regulatory systems and the effect
they exert on major virulence determinants can be found in Table 1.2
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Table 1.2 Major regulators of virulence determinants in S. aureus.
The regulatory
system

Accessory gene
regulator (agr)

Staphylococcal
accessory regulator
(sarA)

Genes regulated

The type of
regulation

Reference

Protein A

-

(136)

Fibronectin-binding
protein

-

(137)

PVL

+

(138)

SspA (V8 serine
protease)

+

(139)

Leukotoxin LukE/D

+

(138)

α-hemolysin

+

(140)

β-hemolysin

+

(141)

δ-hemolysin

+

(141)

agr

+

(142)

Protein A

-

(143)

Fibronectin-binding
protein

+

(137)

PVL

+

(138)

SspA

-

(139)

Leukotoxin LukE/D

+

(138)

α-hemolysin

+

(144)
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S. aureus exoprotein
(sae)

Repressor of toxin
(rot)

δ-hemolysin

+

(143)

Toxic shock
syndrome toxin 1

-

(145)

agr

-

(146)

sarA

-

(146)

Protein A

+

(147)

Fibronectin-binding
protein

+

(147)

SspA

+

(148)

α-hemolysin

+

(149)

β-hemolysin

+

(149)

Coagulase

+

(149)

Toxic shock
syndrome toxin 1

+

(145)

Protein A

+

(150)

α-hemolysin

-

(151)
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1.6( Antimicrobial(Resistance(mechanisms(of(
Staphylococcus,aureus,,
There are two mechanisms by which S. aureus acquires resistance to antimicrobials:
horizontal transfer of an existing resistance gene, and through intrinsic mutations. The
first evidence of resistance in S. aureus was to penicillin, which was mediated by βlactamase encoded by the gene blaZ. Upon antibiotic exposure, a transmembrane signal
transducer, BlaR1, undergoes proteolytic cleavage to inactivate a transcriptional repressor
BlaI, and this de-repression permits expression of blaZ, encoding a β-lactamase. This
enzyme hydrolyzes the β-lactam ring of the antibiotics rendering them ineffective (152,
153). The horizontal transfer of the mec gene accounted for the emergence of methicillin
resistance among S. aureus strains. The mecA encodes the membrane-bound enzyme,
penicillin-binding protein 2a (PBP2a). Typical PBPs catalyze the transpeptidation
reaction required for peptidoglycan cross-linkage, and PBP2a exhibits low affinity to all
agents of the β-lactam class of antibiotics. The expression of mecA is regulated in a
similar fashion to that of blaZ, via the combined action of a sensor-transducer protein and
a transcriptional repressor (MecR1 and MecI, respectively) (154–157). Resistance to
quinolones, on the other hand, is an example of a resistance mechanism mediated by
intrinsic mutation. Fluoroquinolones inhibit DNA gyrase and topoisomerase IV, which
together mitigate DNA supercoiling. Mutations in the conserved quinolone resistancedetermining regions reduce quinolone affinity and are associated with resistance in
clinical isolates (158–160). Two resistance mechanisms to the glycopeptide antibiotic,
vancomycin, have been proposed. The first mechanism is chromosomally mediated,
attributed to mutations that increase synthesis of peptidoglycan and cell wall precursor,
thus preventing the antibiotic from binding to its target (161–164). The second
mechanism is mediated by acquisition of an enterococcal operon that is responsible for
changing the terminal peptide of the cell wall precursor, thus reducing affinity for
vancomycin (161–164).
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1.7( Staphylococcus,aureus,envelope(architecture((
1.7.1(

Cell(envelope(composition(

Gram-positive bacteria are surrounded by a cell wall, composed of layers of
peptidoglycan with attached accessory proteins and teichoic acids, as well as a
cytoplasmic membrane. Teichoic acids can be either in the form of wall teichoic acids or
lipoteichoic acids. Wall teichoic acids are anionic polymers of teichoic acids that are
covalently anchored to the peptidoglycan layer of the cell envelope, whereas the
lipoteichoic acids are those embedded into the cytoplasmic membrane via a lipid moiety.
Wall teichoic acids are comprised of repetitive units of ribitol phosphate or glycerol
phosphate, and are linked to the N-acetylmuramic acid (MurNAc) of the peptidoglycan
through a disaccharide of N-acetylglucosamine (GlcNAc)-1-P and N-acetylmannosamine
(ManNAc) which is followed by glycerol phosphate units (165, 166). In contrast,
lipoteichoic acids are comprised of repetitive units of glycerol phosphate with a D-alanyl
ester or an α- GlcNAc on the second hydroxyl group of the glycerol, and are linked by a
diglucosyl diacylglycerol anchor to the outer leaflet of cytoplasmic membrane (167). S.
aureus utilizes the presence of wall polymers to defend itself from environmental
stressors. Studies have shown that lipoteichoic acids surface-anchoring properties play an
integral role in invading the microvascular endothelial cells of the brain. S. aureus
mutants deficient in lipoteichoic acid membrane anchoring were found to be impaired in
their capability to penetrate the blood-brain barrier thus reducing the chance of
staphylococcal central nervous system disease (168). These wall polymers have also been
linked to resistance to cationic antimicrobial peptides and cationic antibiotics (169, 170).
Gram-positive bacteria are also surrounded by a single cytoplasmic membrane. The
barrier function of the membrane is mediated by its phospholipid bilayer that surrounds
and protects the cytoplasm. There are three major polar phospholipids in S. aureus
membranes: phosphatidylglycerol; lysyl- phosphatidylglycerol; and cardiolipin, which is
the major phospholipid during stationary phase (171). Phospholipid modifications play a
vital role in resistance to host defenses and antimicrobial substances. Failure to modify
phosphatyidylglycerol with L-lysine, to form lysyl-phosphatidylglycerol, reduces the
positive charge of the cell envelope, rendering S. aureus more susceptible to cationic
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antimicrobial peptides (107). Furthermore, membrane phospholipids composition must be
altered to accommodate environmental stressors such as fluctuations in temperature and
pH, and exogenous antimicrobials.

1.7.2(

Membrane(homeostasis(

Fatty acids play important roles in microorganisms, both as an integral component of
cellular membranes, as well as a source of energy. While the biosynthetic pathways for
these fatty acids are rather complex and energetically expensive, a stable membrane
composition must be maintained. The Gram-negative Escherichia coli utilizes the
combination of transcriptional activators and repressors, belonging to the TetR and GntR
families of transcriptional regulators, to control genes involved in fatty acid metabolism
in order to maintain membrane homeostasis (172, 173). This homeostasis especially must
be maintained upon exposure to exogenous fatty acids that could interfere with
membrane fluidity. Host-derived fatty acids are either utilized as a precursor in the
membrane phospholipid biosynthetic pathway or degraded via the β-oxidation pathway to
be utilized as an energy source for the bacteria. Fatty acid biosynthesis is regulated via
the TetR family regulator, FabR, and fatty acid degradation is regulated via the GntR
family regulator, FadR (172, 174). FadR is a repressor of the β-oxidation pathway (fad
regulon) and an activator for the fabA and fabB genes, which in turn are under the
regulation of the repressor FabR, and acyl-CoA thioesters are the ligand that modulates
binding of FadR and FabR to their operator DNA (173–175). Therefore, membrane lipid
homeostasis in E. coli is a product of a transcriptional regulator with dual functionality
that contributes to both fatty acid synthesis and degradation.
regulation of lipid homeostasis in E. coli can be seen in Figure 1.1
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An overview of the

In the absence of acyl-CoA
FadR

Repression of fad genes
involved in fatty acid
degradation (β-oxidation)
pathway

fad

FadR
fabA
FabR

Activation of fab genes
involved in fatty acid
biosynthesis pathway

FadR
fabB

In the presence of acyl-CoA
FadR

Activation of fad genes
involved in fatty acid
degradation (β-oxidation)
pathway

fad

FabR
fabA
FadR

Repression of fab genes
involved in fatty acid
biosynthesis pathway

FabR
fabB

Figure 1.1 Regulation of lipid homeostasis in E. coli. Exogenous fatty acids are
converted to acyl-CoAs after entry into the cell. In the absence of acyl-CoA, the
transcriptional regulator FadR acts as a repressor of the fad regulon to repress fatty acid
degradation, and as an activator of fabA and fabB to activate fatty acids biosynthesis. The
genes fabA and fabB are also under the control of the transcriptional repressor FabR. In
the presence of acyl-CoA, FadR dissociates from its operator DNA, resulting in the
expression of fad genes to activate fatty acid degradation, as well as repression of the fab
genes to repress fatty acid synthesis (176, 177).
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Moreover, optimal membrane fluidity is governed by the fatty acid composition of
phospholipids; both saturated and unsaturated. Saturated fatty acids are produced to
increase membrane rigidity, whereas unsaturated fatty acids are produced to increase
membrane fluidity, as is the case when the bacteria are exposed to higher and lower
growth temperatures, respectively (178). For instance, Pseudomonas aeruginosa employs
two desaturase systems, in addition to the Fab pathway, to regulate fatty acid biosynthesis
to maintain membrane homeostasis. The first system is DesA which modifies existing
membrane phospholipids to accommodate fluctuations in fluidity. The second desaturase
system is DesB which alters saturated fatty acids of exogenous source, such as those
lipids in the pulmonary surfactant encountered by P. aeruginosa, to produce unsaturated
fatty acids to maintain optimal membrane fluidity. DesB is regulated at the transcriptional
level by DesT which is a regulator that senses environmental fatty acids, and
differentiates between saturated and unsaturated acyl-CoA substrates. In the presence of
unsaturated acyl-CoA, DesT binds to an operator DNA located in the promoter region of
desCB, to repress transcription of these genes which are necessary for production of
unsaturated fatty acids. Conversely, the presence of saturated acyl-CoA causes the release
of DesT from the operator DNA and the subsequent expression of desB, which in turn
introduces double bonds into the acyl-CoA products of exogenous fatty acids and restores
optimal membrane fluidity (179–181).
Comparatively, transcriptional regulation of membrane lipid homeostasis in Grampositive bacteria is less well understood. The most detailed studies have been conducted
in Bacillus subtilis, where a two-component desaturase system encoded by desK and
desR regulates the membrane-bound acyl desaturase, DesA. This desaturase system
senses temperature fluctuations and since B. subtilis is incapable of de novo synthesis of
unsaturated fatty acids, the bacterium employs DesA to desaturate existing phospholipids
in order to maintain membrane fluidity (182, 183). Additionally, B. subtilis also employs
a transcriptional regulator, FadR, which controls genes involved in fatty acid degradation.
Unlike FadR of E. coli, which is a GntR regulator, FadR of B. subtilis is a TetR family
regulator. Similar to E. coli, B. subtilis FadR is a repressor of genes involved in fatty acid
degradation, and acyl-CoA is the ligand that modulates binding of FadR to its operator
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DNA. In the presence of exogenous fatty acids, the promoters repressed by FadR are derepressed and fatty acids are degraded to be utilized as a carbon source (184)
Furthermore, B. subtilis employs transcriptional regulation to sense the status of the
intracellular pool of fatty acids to maintain lipid homeostasis and optimal membrane
fluidity. The repressor FapR regulates the expression of genes involved in fatty acid and
phospholipid synthesis in response to the cellular levels of malonyl-CoA. Elevated levels
of malonyl-CoA are indicative of diminished fatty acid and phospholipid synthesis which
in turn results in the de-repression of FapR-mediated genes that are involved in lipid
biosynthetic machinery (185, 186). FapR is the first global transcriptional regulator that is
highly conserved among Gram-positive bacteria (185, 187). FapR was first characterized
and purified from B. subtilis, and was subsequently found to be conserved in other
organisms such as S. aureus and Listeria monocytogenes. Similar to FapR in B. subtilis,
staphylococcal FapR senses malonyl-CoA to monitor lipid synthesis in a feed-forward
mechanism to maintain membrane homeostasis (185, 188). This feed-forward mechanism
involves recognition of an upstream biosynthetic product to regulate the transcription of
the genes involved in the lipid biosynthetic machinery.
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Figure 1.2 Regulation of lipid homeostasis in B. subtilis. A. Exogenous fatty acids are
converted to acyl-CoAs after entry into the cell. In the absence of acyl-CoA, the
transcriptional regulator FadR acts as a repressor of the fad regulon to repress fatty acid
degradation. In the presence of acyl-CoA, FadR dissociates from its operator DNA,
resulting in the activation of fatty acid degradation pathway to utilize the exogenous fatty
acids as a carbon source. B. FapR is responsive to the cellular status of fatty acid
biosynthesis. Malonyl-CoA is the ligand modulating FapR binding to its operator DNA.
In low levels of malonyl-CoA, fatty acid biosynthesis genes are repressed. In the
presence of malonyl-CoA, FapR dissociates from its operator DNA, resulting in the
expression of fap genes to activate fatty acid and phospholipid synthesis.
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1.8( Fatty(acid(machinery(of(Staphylococcus,aureus,,
1.8.1(

Phospholipid(composition((

There are three major phospholipids in S. aureus membranes: phosphatidylglycerol;
lysyl- phosphatidylglycerol; and cardiolipin (171). These phospholipids play a crucial
role in preserving membrane biophysical properties, and particularly, the fatty acid
composition of phospholipids is the key determinant of membrane fluidity (189) . Unlike
B. subtilis that possesses a gene encoding a membrane phospholipid desaturase for the
synthesis of unsaturated fatty acids, S. aureus does not possess such desaturase and thus
is incapable of producing these fatty acids (182). Instead, a combination of branched- and
straight-chain fatty acids are present in staphylococcal membranes. Branched-chain fatty
acids are the predominant fatty acids in S. aureus phospholipids, comprising 55-65% of
the total fatty acids

(189, 190). Branched-chain fatty acids are synthesized from

branched-chain amino acids; these include leucine- and valine-derived (iso) fatty acids,
and isoleucine-derived (anteiso) fatty acids, with the latter in particular promoting
increased membrane fluidity (189, 191).

1.8.2(

Phospholipid(synthesis((

The biosynthetic pathway of staphylococcal branched-chain fatty acids starts when the
amino acids leucine, isoleucine and valine undergo a transamination reaction mediated by
the branched-chain amino acid transaminase BAT. The resulting branched-chain α-keto
acid then undergoes a decarboxylation reaction mediated by α-keto acid dehydrogenase
(BKD), resulting in the formation of branched-chain acyl coenzyme A derivatives which
are the precursor for fatty acids biosynthesis. The branched-chain acyl coenzyme A
derivatives, in combination with malonyl-ACP, are then utilized by the β-ketoacyl-ACP
synthase III (FabH) to generate β-ketoacyl-ACP. This in turn undergoes a reduction
reaction mediated by FabG reductase, a dehydration reaction mediated by FabZ and a
reduction reaction mediated by FabI, resulting in the formation of saturated acyl-ACP.
The enzyme FabF catalyzes the condensation reaction permitting further product
elongation. The resulting long chain acyl-ACP is then used in the generation of the
phospholipid precursor, phosphatidic acid (189, 192–196).
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The peripheral membrane protein PlsX is responsible for transferring the acyl group from
Acyl-ACP to an inorganic phosphate, forming an acylphosphate product, which can then
be used by an integral plasma membrane protein, PlsY. This interaction between PlsY
and the acylphosphate product, in the presence of glycerol-3-phosphate, results in the
formation of Acyl-G3P, which is then acylated by the integral membrane protein PlsC,
forming phosphatidic acid that represents the key intermediate in membrane phospholipid
formation. Phosphatidic acid is subsequently used, in the presence of cytidine
triphosphate, to synthesize cytidine diphosphate diacylglycerol through the action of
phosphatidate cytidylyltransferase. Phosphatidylglycerol-phosphate is then generated
upon the replacement of cytidine monophosphate with glycerol phosphate. The
dephosphorylation of phosphatidylglycerol-phosphate results in the formation of
phosphatidylglycerol which is the core phospholipid in S. aureus (196–201). An
overview of fatty acid and phospholipid biosynthesis in S. aureus can be seen in Figure
1.3
In addition to the fatty acids produced by the fatty acid synthase machinery mentioned
above, S. aureus is also capable of utilizing fatty acids of exogenous source. Upon entry
into the cell by flipping across the membrane leaflet, exogenous fatty acids are processed
by the fatty acid kinase machinery. This machinery includes a kinase domain protein,
FakA, and a fatty acid binding protein FakB1 and FakB2 for binding saturated and
unsaturated fatty acids, respectively. Exogenous fatty acids bind FakB, and after
phosphorylation by FakA, are incorporated into the phospholipid directly, or indirectly
after passing through an extension cycle by the FASII machinery (202). During the
extension cycle, acyl chains are extended by two carbons via four enzymatic reactions.
Extension is initiated by an elongation condensing enzyme, FabF, and the resulting βketoacyl-ACP is then reduced by the reductase, FabG. Subsequently, β-hydroxyacylACP undergoes a dehydration reaction through the action of FabZ. The resulting trans-2enoyl-ACP undergoes a reduction reaction that is catalyzed by the reductase FabI to
complete the extension cycle (203–206). The peripheral membrane protein PlsX is
responsible for transferring the acyl group from the extended fatty acid product to an
inorganic phosphate, forming an acylphosphate product, which can then be used by an
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integral plasma membrane protein, PlsY. This interaction between PlsY and the
acylphosphate product results in the acylation of glycerol-3-phosphate forming the first
intermediate in membrane phospholipid formation, known as lysophosphatidic acid.
Lysophosphatidic acid is then acylated by the integral membrane protein PlsC, forming
phosphatidic acid that represents the core intermediate in membrane phospholipid
formation (197–200). An overview of exogenous fatty acid utilization in S. aureus can
be seen in Figure 1.4
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Figure 1.3 Overview of fatty acid and phospholipid biosynthesis in S. aureus.
Synthesis of staphylococcal branched-chain fatty acids starts when the amino acids
leucine, isoleucine and valine undergo a transamination followed by a carboxylation
reactions reaction, resulting in the formation of branched-chain acyl coenzyme A
derivatives which are the precursor for fatty acids biosynthesis. The branched-chain acyl
coenzyme A derivatives, in combination with malonyl-ACP, are then utilized by FabH to
generate β-ketoacyl-ACP. This in turn undergoes a reduction reaction by FabG, a
dehydration reaction by FabZ and a reduction reaction by FabI, resulting in the formation
of saturated acyl-ACP. The enzyme FabF catalyzes the condensation reaction permitting
further product elongation where the resulting acyl-ACP can undergo additional rounds
of elongation by FabG, FabZ and FabI. For simplicity, the steps shown here are
unidirectional. Subsequently, the resulting long chain acyl-ACP is then used in the
generation of the phospholipid precursor, phosphatidic acid. The protein PlsX is
responsible for transferring the acyl group from Acyl-ACP to an inorganic phosphate,
forming an acylphosphate product, which can then be used by PlsY to form acyl-G3P.
The latter in turn is acylated by PlsC, forming phosphatidic acid which is subsequently
used, in the presence of cytidine triphosphate, to synthesize cytidine diphosphate
diacylglycerol

through

the

action

of

phosphatidate

cytidylyltransferase.

Phosphatidylglycerol-phosphate is then generated upon the replacement of cytidine
monophosphate with glycerol phosphate, and subsequently dephosphorylated to form
phosphatidylglycerol which is the core phospholipid in S. aureus membranes. Figure is
adapted from Schiebel et al. and Kuhn et al. (193, 196).
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Figure 1.4 Overview of exogenous fatty acid utilization by S. aureus. Upon entry into
the cell, exogenous fatty acids (FA) are processed by the fatty acid kinase machinery; FA
are bound by FakB and phosphorylated by FakA. Subsequently, phosphorylated fatty
acids are either are incorporated into the phospholipid directly (A), or indirectly after
passing through an extension cycle by the FASII machinery (B). Figure is adapted from
Parsons et al., and Yao and Rock (202, 207).
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1.8.3(

Lipids(as(antimicrobials((

The skin is the first line of defense against microbial infection. One of the host innate
defense elements on the skin is antimicrobial long-chain unsaturated fatty acids. The
main source of these fatty acids is the sebum secreted by the sebaceous glands and
differentiating keratinocytes present in the stratum corneum of the epidermis (208). The
sebum consists of squalene, wax monoesters, triglycerides, and small amounts of
cholesterol and cholesterol esters (209). As the sebum’s constituents stream outwards
through the hair follicle associated with the sebaceous glands, the triglycerides undergo
enzymatic hydrolysis to produce unsaturated free fatty acids (uFFA) on the skin surface.
The principal uFFA derived from sebaceous triglycerides is sapienic acid, which is a 16carbon fatty acid with one degree of unsaturation that has potent bactericidal property
against MRSA (208). Linoleic acid was identified as the major uFFA in human nasal
secretion and is also present in S. aureus abscesses, a hallmark of S. aureus skin and soft
tissue infections (210–212). Humans deficient in the production of uFFAs are more
susceptible to S. aureus skin infections (213).
Although S. aureus possess the genes coding for enzymes involved in fatty acid
degradation, studies have ruled out their involvement in exogenous fatty acid utilization
(214). Alternatively, the only metabolic fate of exogenous uFFAs is through
incorporation into the membrane phospholipid (194, 215). This incorporation is the rate
limiting step such that when the levels of exogenous uFFAs exceeds that of the
phospholipid biosynthetic machinery, uFFAs accumulate in the membrane and become
detrimental (216). Although it has been long recognized that uFFAs have membrane
damaging properties (217, 218), the exact mechanism by which these uFFAs exert their
toxicity remained debatable. Several mechanisms have been proposed; these include
uFFAs increasing the permeability of bacterial membranes due to their surfactant action,
and disrupting the anisotropic nature of membranes by interfering with protons
movement across the membrane and subsequently ATP synthesis (219, 220). Other
reports have proposed that the toxic effects of uFFAs are mediated through a peroxidative
process and through inhibiting fatty acid synthesis by acting as selective inhibitors of the
enoyl –acyl carrier protein reductase (FabI) (221, 222). However, recent reports confirm
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that exogenous uFFAs disrupt the cytoplasmic membrane integrity, resulting in
dissolution of the proton gradient across the membrane. This in turn leads to leakage of
cellular metabolites and low-molecular weight proteins, and the eventual cessation of
macromolecular biosynthetic pathways and loss of cellular viability (216).
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Table 1.3 Summary of proposed mechanisms of uFFA toxicity.
Target

Mechanism

Reference

Cytoplasmic
membrane

Uncouple the electron transport chain

(223, 224)

Cytoplasmic
membrane

Impede oxidative phosphorylation

(220)

Cytoplasmic
membrane

Surfactant action that increases membrane
permeability

(219)

Cytoplasmic
membrane

Increase membrane fluidity leading to cell
lysis

(218, 225)

Cytoplasmic
membrane

Dissolution of the proton gradient across
the membrane and subsequent release of
low molecular-weight proteins

(216)

Fatty acid synthetic
machinery

Enzymatic inhibition

(222)

Cellular viability

Oxidative stress

(221, 226)
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Although exogenous uFFAs display antimicrobial properties, bacterial species are
equipped with intrinsic mechanisms of resistance to these uFFAs. External structures
such as the outer membrane and cell wall of Gram-negative and positive bacteria,
respectively, mediate protection against uFFAs through several mechanisms that are
briefly reviewed here. First, transcriptomics and proteomics studies show that upon
exposure to exogenous uFFAs, S. aureus upregulates genes involved in carotenoid
biosynthesis, as well as those in cellular energy metabolism, peptidoglycan, and call wall
biosynthetic pathways (227). Cell wall components play an integral role in S. aureus
susceptibility to antimicrobial uFFAs, as wall structure, thickness and properties can
impede the entry of these uFFAs. It has been proposed that the iron-regulated surface
determinant, IsdA, is involved in resistance to uFFAs where this cell wall anchored
protein modifies cellular hydrophobicity. The C domain of IsdA extends into the
staphylococcal cell wall, altering its charge and hydrophobicity thus rendering the cells
less susceptible to host antimicrobial peptides and fatty acids that rely on hydrophobic
interactions to penetrate the cellular membrane and manifest their effects (227, 228).
Other reports suggest that S. aureus counteracts the uFFA-mediated increase in
membrane fluidity by upregulating the production of staphyloxanthin, leading to a direct
correlation between membrane stability, cellular pigmentation, and uFFAs-induced
cellular killing (218, 227, 229). The production of staphyloxanthin is regulated by the
sigma B (σB) regulon as a general stress response to the presence of uFFAs (227).
Additionally, it has been proposed that wall teichoic acids confer resistance to uFFAs, by
acting as a filter to restrict their passage across the cell wall, in a structure-specific
manner, and cells lacking teichoic acids exhibit enhanced leakage of intracellular content
(216, 230). Moreover, the fatty acid modifying enzyme (FAME), responsible for fatty
acid esterification, has also been linked to uFFA tolerance. FAME can esterify
bactericidal fatty acids that are present in staphylococcal abscesses to various alcohols,
thus enabling bacterial survival within tissues (227, 231). As is the case with the majority
of antimicrobial resistance, it can be anticipated that resistance to uFFAs should also be
mediated through efflux pumps. Neisseria gonorrhoea, for instance, exhibits an efflux
system dedicated to extrusion of hydrophobic antimicrobials such as free fatty acids and
bile salts (232, 233). Similarly, there are some reports of efflux pumps contributing to S.
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aureus resistance to skin antimicrobials such as fatty acids and polyamines. Tet38 is a
multidrug efflux transporter that confers resistance to tetracycline as well as palmitoleic
acid, one of the main uFFA in human nasal secretion (221, 234). Tet38 is implicated in S.
aureus survival and colonization on the skin due to its ability to transport antimicrobial
free fatty acids thus conferring resistance to them (234). However, this efflux pump is not
specific just for uFFAs, as it contributes to tetracycline resistance as well, and therefore a
specific fatty acid efflux pump is yet to be identified in S. aureus.
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Table 1.4 Summary of uFFA resistance mechanisms proposed to date.
Target

Mechanism

Reference

Cell wall physiology

Decrease cellular hydrophobicity and thus
prevent uFFA penetration

(228)

Membrane stability

Increase staphyloxanthin production to
counteract the uFFA-mediated increase in
membrane fluidity

(218, 227, 229)

Wall teichoic acids

Prevent binding of uFFAs

(216, 230)

uFFA transport

Tet38-mediated efflux of uFFAs outside
the cell

(234)

uFFA processing

FAME- medicated esterification of uFFAs
to various alcohols

(227, 231)
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1.9( Bacterial(efflux(pumps(
One of the greatest innovations in modern medicine is the introduction of antibiotics in
clinical practices to treat the otherwise life-threatening infectious diseases. However,
bacterial pathogens were able to circumvent this progress by developing resistance
mechanisms leading to infectious diseases that are once again, a major problem in the
hospital and community settings. The World Health Organization continuously urges for
the development of new bacterial therapeutic targets to combat the life-threatening
multidrug resistance (235, 236).
The efficacy of antimicrobial compounds can be abrogated by a number of mechanisms
including: reduced uptake; enzymatic inactivation; target site modification; and efflux
from the cell (237, 238). There are five primary families of multidrug efflux pumps:
resistance nodulation cell division (RND); major facilitator superfamily (MFS); ATP
binding cassette (ABC) family; multidrug and toxic compound extrusion (MATE) family;
and small multidrug resistance (SMR) family. In addition to their notable functions in
multidrug resistance, the RND efflux pumps have been extensively studied for their roles
in fatty acid efflux (239, 240). The most well characterized member of the RND family
of multidrug efflux pumps is the AcrB pump of E. coli. AcrB uses proton motive force to
extrude hydrophobic substances such as antibiotics, bile salts, and a range of cellular
metabolites. This tripartite efflux system in E. coli is composed of the trimeric AcrB that
spans the inner membrane, TolC which is an outer membrane channel, and the
periplasmic adaptor protein AcrA (241–243). Another RND family membrane protein
that has a role in lipid efflux is the mycobacterium membrane protein large (MMPL)
group of proteins in Mycobacterium tuberculosis. MMPLs are co-localized with lipidmetabolizing enzymes, and are involved in the transport of methyl-branched lipids (244).
MMPL-mediated lipid pathways have been implicated in bacterial intracellular
persistence, and four of the MMPL proteins appear to be indispensable for M.
tuberculosis in fully maintaining virulence in mice (244).
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1.10(TetR(family(of(transcriptional(regulators(and(their(
biological(functions((
Transcriptional regulators are the key to most microbial adaptation strategies. These
regulators normally contain a DNA- and ligand- binding domain that can be used to sense
environmental signals and elicit a downstream response at the transcriptional level. There
are many families of transcriptional regulators that have been grouped based on structural
and functional similarities, such as the helix-turn-helix motif, which is the most common
DNA-binding motif among prokaryotes (245–247). Members of these families have
either an activation or a repression function, with a few families that display
unconventional dual roles in activation and repression. Members of the LysR, IcIR,
MarR, and Crp families of transcriptional regulators have displayed dual roles (248–251).
Recently, there have been few reports of members of the TetR family of transcriptional
regulators that display dual functionality (252, 253).
TetR family regulators (TFRs) have been well documented for their roles in
environmental adaptation and antibiotic resistance (254). There are more than 2500 TFRs
with functions ranging from multidrug resistance, biosynthesis of antibiotics, and
pathogenicity in both Gram-positive and Gram-negative bacteria (255). TFRs are named
after the well-characterized TetR, a repressor that controls expression of a membraneassociated protein, TetA, that exports tetracycline out of the bacterial cell. tetR and tetA
are divergently transcribed, and the tetR gene product controls expression of both tetA
and tetR. When tetracycline is present and associated with Mg2+, it binds to the TetR
protein leading to a conformational change that renders TetR unable to bind to the DNA.
As a result, tetR and tetA, both of which are repressed by TetR, are expressed (256–260).
A well-documented staphylococcal TFR is QacR, which is a repressor regulating the
expression of QacA, a multidrug efflux pump. Lyon et al. in 1984 showed that the S.
aureus plasmid pSK1 encodes resistance to quaternary ammonium antiseptic compounds.
This resistance is mediated by energy-dependent efflux encoded by the qacA gene that
belongs to a regulatory circuit similar to that of the efflux-mediated resistance to
tetracycline. This plasmid-encoded system also contained a transcriptional regulator with
sequence similarity to the helix-turn-helix motif of the transcriptional repressor that
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governs tetracycline-resistance in Gram-negative bacteria (261–264). By 1998, it was
confirmed that QacA contains 14 transmembrane domains and that it belongs to the
major facilitator superfamily of transporters, and that QacR is the repressor regulating the
expression of this transporter (265, 266). QacR functions as a homodimer with an Nterminal DNA-binding domain recognizing an operator sequence located downstream
from the divergent qacA promoter (266–268). This binding is considered unorthodox for
a repressor as it may not physically block the binding RNA polymerase directly, but
rather it hinders the transition of the transcription machinery. The regulator of
intercellular adhesion (ica) operon of S. epidermidis is a TFR that is responsible for
regulating the synthesis of polysaccharide intercellular adhesin (PIA) and, subsequently,
biofilm formation (269). Two IcaR homodimers bind cooperatively to an operator site
located upstream of the start codon of icaA to repress its transcription (270, 271). Upon
ligand binding of streptomycin and gentamicin, IcaR dimers undergo a conformational
change in the DNA binding domain, and the subsequent transcription of the divergent
icaADBC operon (272). Cramton et al in 1999 showed that the ica locus is not only
present in S. aureus, but is also implicated for biofilm formation (273); however, in S.
aureus, the teicoplanin-associated locus regulator (TcaR), a member of the MarR family
of transcriptional regulators, is also a repressor of the ica operon (272).
Other examples of TFRs include: the AmeR of Agrobacterium tumefaciens which is a
regulator of an RND- efflux system; AmrR of Pseudomonas aeruginosa which is a
regulator of an efflux pump involved in aminoglycoside resistance; and BpeR of
Burkholderia pseudomallei which is a repressor of an RND pump involved in
gentamyicin, streptomycin, and erythromycin resistance (274–276). Similarly, resistance
to the anti-tuberculosis drug ethionamide in M. tuberculosis is mediated by the TetR
regulator EthR, and resistance to hydrophobic antimicrobial agents that target N.
gonorrhoea is mediated by MtrR (233, 277–279). TFRs are also involved in regulation of
virulence genes, such as HapR, which is a density-dependent regulator of virulence in
Vibrio cholera (280, 281).
Additionally, several TFRs have a role in regulation of fatty acid efflux. AcrR is a
repressor of the multidrug efflux pump AcrAB in E. coli; a prototypic member of the
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RND family of efflux pumps. AcrR interacts with the acr promoter located in the
intergenic segment between acrR and acrAB. This interaction between AcrR and the
promoter region is responsive to accumulation of cellular metabolites and bile salts as
well as global stress signals. In the presence of inducing ligand, AcrR is de-repressed and
functions in combination with global transcriptional activators to enable efflux pump
expression (282–285). Other TFRs that have roles in lipid efflux include: CmeR from
Campylobacter jejuni and MtrR from N. gonorrhea. CmeR is a repressor of an RNDefflux pump, CmeABC, that is responsive to accumulation of amphipathic bile salts
(286–289). Similarly, MtrR is a repressor of an RND pump, MtrCDE, the efflux of which
enables gonococcal growth on mucosal surfaces that are enriched in fatty acids and bile
salts. Additionally, MtrR is a repressor of a MarR family transcriptional regulator, FarR,
which in turn is a repressor of the MFS efflux pump FarAB. Therefore, MtrR also
functions as a positive regulator of the FarAB efflux pump which mediates resistance to
antimicrobial fatty acids (233, 279, 290–292).

1.11(Rationale(and(hypothesis((
CA-MRSA strains are particularly efficient in colonization, transmission, and causing
invasive skin and soft tissue infections (6). Our laboratory strain of choice is USA300,
the dominant CA-MRSA strain in the United States, accounting for 98% of MRSA
infections presenting to emergency departments (293). USA300, which was isolated in
September 2000, has been linked to infection outbreaks in at least 21 American states,
Canada, and Europe (132). Further, this isolate is more resistant to killing by
polymorphonuclear leukocytes (132). To persist on human skin, S. aureus must cope with
uFFAs; a component of human innate defense mechanisms. Although genome
sequencing and molecular typing have provided a better understanding of the pathogenic
success of USA300, detailed knowledge of the specific molecular determinants,
especially in regards to uFFA resistance, is still lacking (294, 295). Although S. aureus
possess the genes coding for enzymes involved in fatty acid degradation, studies have
ruled out their involvement in exogenous fatty acid utilization (214). Therefore, the only
metabolic fate for exogenous uFFAs is through their incorporation into the membrane
phospholipid. This incorporation step is the rate-limiting step, such that when the rate of
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fatty acid import exceeds that of incorporation, excess free fatty acids accumulate in the
membrane, ultimately resulting in cell death (202, 214, 216).
To better understand the factors that contribute to S. aureus adaptation to uFFA, our
laboratory evaluated the growth of S. aureus USA300 in the presence of physiological
concentrations of uFFA that would normally be encountered on the skin and in the
anterior nares. Arsic et al. showed that uFFA can induce the staphylococcal proteolytic
cascade (296). Additionally, Arsic et al. showed that unsaturated linoleic and sapienic
acids are sub-inhibitory at 25 µM and bactericidal at 100 µM, whereas a 50 µM
concentration caused a 10-12 hour lag phase after which bacteria resumed growth (296).
It was established that the profile of secreted proteins and virulence factors is influenced
by exogenous uFFAs, suggesting a possible regulatory mechanism of virulence in
response to uFFAs.
To identify genes that may confer intrinsic resistance to uFFA, S. aureus USA300 was
selected for growth at elevated concentrations of linoleic acid after which single colonies
were selected for DNA isolation and genome sequencing on the Ion Torrent Platform to
identify single nucleotide polymorphisms (SNP) in 7 fatty acid resistant (FAR) clones.
Two of these clones contained SNP causing a His121>Tyr substitution in
SAUSA300_2490 gene. Using domain enhanced lookup time accelerated BLAST, the
amino acid sequence of SAUSA300_2490 had 99% homology to TFRs and structure
prediction using homology modeling server, Phyre2, predicted that SAUSA300_2490
shares 99.8% amino acid sequence similarity with TFRs such as FadR, a regulator of
fatty acid degradation in Thermus thermophilus.
TFRs typically exert their effect on divergent genes. Bioinformatics analyses revealed
that SAUSA300_2489, which is divergently transcribed from SAUSA300_2490, encodes a
gene product that belongs to the Resistance-Nodulation-Cell Division (RND) superfamily
of proteins, which promote proton-antiport dependent efflux mechanisms. To date, there
is no evidence of a specific uFFA efflux mechanism in S. aureus, and since
SAUSA300_2490 was found through the in vitro selection of variants with increased
resistance to linoleic acid, I speculated that this gene may contribute to uFFA resistance.
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I hereafter refer to SAUSA300_2490 as farR for regulator of fatty acid resistance, and to
SAUSA300_2489 as farE, for an effector of fatty acid resistance. Therefore, I hypothesize
that farR functions to regulate expression of a fatty acid efflux pump encoded by farE
and that a SNP in farR is sufficient to confer resistance to fatty acids. The specific aims
of this thesis were to first confirm that the resistance to uFFAs in S. aureus is inducible,
and examine the role of farR and farE in this induction. Second, I wanted to examine the
nature of regulation that FarR exerts on farE, and define the exact operator sites that
support FarR binding. Third, I aimed to examine how this novel regulatory system is
linked to fatty acid detoxification mechanism both in vitro and in vivo.
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2.1( Introduction(
Staphylococcus aureus has a dichotomous relation with human hosts, being able to
establish an asymptomatic commensal relationship, but also historically known as a
leading cause of human infectious morbidity and mortality. Significantly, death attributed
to S. aureus in the United States is now comparable to mortality rates for AIDS,
tuberculosis, and viral hepatitis (1-3). Not surprisingly, therefore, S. aureus has been the
subject of intensive research on mechanisms of pathogenesis, acquisition and transfer of
antibiotic resistance, and efforts to identify potential vaccine antigens (4-6). Until the late
1990’s, much of this was directed towards hospital-associated strains of methicillin
resistant S. aureus (HA-MRSA), to address the anticipated emergence of superbugs that
would be resistant to all clinically useful antibiotics (7, 8). However, a new threat
emerged in the late 1990’s with community acquired MRSA (CA-MRSA). Although
these strains evolved in the community setting, one notorious strain known as USA300
has achieved pandemic status across North America, and is now the leading cause of S.
aureus infections, irrespective of community or hospital origins (9, 10). This has
engendered greater attention towards identifying mechanisms of S. aureus persistence on
human hosts, and host-to-host transmission.
Approximately 25% of humans are persistently colonized by S. aureus, where the
preferred site of colonization is the anterior nares and, among colonized individuals, the
bacterium is also frequently recovered from other body sites, including the axillae,
perineum, hands, chest and limbs (11). Accordingly, its ability to persist on skin is an
important mediator of transmission, as underscored by the recent discovery that the
hyper-transmissible USA300 strain has overcome one of the innate defense barriers of the
skin through horizontal gene transfer with S. epidermidis, to acquire resistance to toxic
polyamines that restrict the growth of other S. aureus strains (12, 13). Other innate
defence barriers of the skin include its acidic pH, and antimicrobial fatty acids, foremost
of which is sapienic acid that is released from triglycerides secreted by the sebaceous
glands (14, 15). Nasal secretions also contain antimicrobial fatty acids; primarily linoleic, arachidonic- and palmitoleic acid, or their corresponding cholesterol esters (16), and
infected abscess tissue also contains abundant antimicrobial fatty acids (17, 18).
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Consequently, S. aureus is exposed to antimicrobial fatty acids, not only during
colonization, but also during infection and, as such, it is reasonable to hypothesize that it
has evolved mechanisms of intrinsic resistance.
Among mechanisms that have been described, cell surface teichoic acids can selectively
restrict the access of palmitoleic acid to the cytoplasmic membrane (19), and a cell
surface protein IsdA that is expressed in response to iron-limiting conditions also restricts
the access of palmitoleic acid, or its isomer sapienic acid to the cytoplasmic membrane
(20). Others have reported that tet38, encoding a Major Facilitator Superfamily (MFS)
efflux pump, promotes resistance to palmitoleic acid (21). Expression of tet38 was
induced by palmitoleic acid, but not by linoleic acid, which suggested that there could be
distinct mechanisms for coping with different antimicrobial fatty acids. Importantly,
linoleic acid is an essential fatty acid for humans, which must be obtained from dietary
sources, and is an essential precursor for synthesis of arachidonic acid. These two
unsaturated fatty acids comprise a major proportion of unsaturated fatty acids in
membrane phospholipid (22, 23). Therefore, the ability to sense and respond to linoleic
acid could represent a specific sensory mechanism to signal colonization or infection of a
human host, and yet specific mechanisms for regulating gene expression and intrinsic
resistance in response to linoleic acid have not been reported.
To address this, we drew from our previous observation that exposure of S. aureus
USA300 to a sub-inhibitory (25 µM) concentration of linoleic acid, caused a robust
induction of secreted protease expression, which led to proteolytic processing of a
secreted glycerol ester hydrolase, Geh (24). We subsequently noted that when S. aureus
cultures were supplemented with a trilinolein triglyceride substrate, Geh activity quickly
liberated growth inhibitory concentrations of linoleic acid (25). Moreover, 50 µM free
linoleic acid imposed a 10-12h growth delay in cultures of S. aureus USA300, which was
then followed by unimpeded exponential growth, and similar results were obtained with
50 µM trilinolein in wild type geh proficient S. aureus USA300, whereas growth of a geh
deficient mutant was unaffected by 50 µM trilinolein (24, 25). From these observations,
we hypothesized that, in addition to the induction of expression of secreted proteases,
there should also be an inducible mechanism for resistance of S. aureus to linoleic acid.
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In related studies, selection of S. aureus strains that were able to grow at elevated
concentrations of glycopeptides led to the identification of point mutations in the vraS
sensor of antimicrobial glycopeptides (26, 27). Therefore, we adopted a similar strategy,
by conducting comparative genome sequencing of USA300 clones that were selected for
their ability to initiate growth without a lag phase, when inoculated into media containing
50 µM linoleic acid. We now provide the first description of a novel gene pair farR-farE
(fatty acid resistance) constituting divergently transcribed genes that, respectively,
encode a regulator and effector of S. aureus resistance to linoleic and arachidonic acid.

2.2( Materials(and(methods((
2.2.1(

Bacterial(strains(and(growth(conditions((

A list of bacterial strains and plasmids that were used or constructed for this study is
provided in Table 2.1. S. aureus cultures were maintained as frozen stocks (-80ºC) in
20% glycerol, and streaked on TSB agar when required. TSB was supplemented, when
required, with 10 µg/mL of erythromycin or chloramphenicol for propagation of strains
bearing resistance markers. E. coli strains were grown on LB agar, or LB broth
containing 100 µg/mL ampicillin when required. Unless otherwise stated, all cultures
were grown at 37°C, and liquid cultures were incubated on an orbital shaking platform at
180 rpm.
For experimental purposes, inoculum cultures of S. aureus were prepared by transferring
cells, from a single colony, into 13 mL polypropylene tubes containing 3 mL of TSB
supplemented with antibiotic, as required, followed by overnight incubation. After
determination of optical density at 600 nm (OD600), aliquots of the overnight cultures
were diluted into 25 mL of medium in 125 mL flasks, to achieve an initial OD600
equivalent to 0.01. To supplement media with different fatty acids, a 5 mM stock
concentration was initially prepared in sterile TSB containing 1% DMSO, and then
diluted into sterile TSB supplemented with 0.1% DMSO, to achieve the desired
concentration of fatty acids, ranging from 5 µM to 100 µM.
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Table 2.1 Strains and plasmids used in Chapter 2.
Strain or plasmid

Description

Source or
reference

Strains:
S. aureus:
USA300 LAC

Community associated MRSA; wild type
strain cured of resistance plasmids

(24)

RN4220

rK− mK+; capable of accepting foreign DNA

(32)

NE1393

Transposon insertion in SAUSA300_2490;
Ermr

(34)

NE2336

Transposon insertion in SAUSA300_2489;
Ermr

(34)

USA300farR::ΦNΕ

USA300 LAC recipient of transposon from
NE1393

This study

USA300farR::ΦNΕ +
pLIfarR

farR::ΦNΕ complemented with native farR,
cloned in pLI50; Ermr, Cmr

This study

USA300farR::ΦNΕ +
pCNfarR

farR::ΦNΕ complemented with pCNfarR for
cadmium inducible expression; Ermr, Cmr

This study

USA300farE::ΦNΕ

USA300 LAC recipient of transposon from
NE2336

This study

USA300farE::ΦNΕ +
pLIfarE

farE::ΦNΕ complemented with native farE,
cloned in pLI50

This study

USA300farE::ΦNΕ +
pLI50

USA300farE::ΦNΕ with empty pLI50 vector;
Cmr

This study

USA300Δtet38

USA300 LAC with internal deletion of tet38
(SAUSA300_0139)

This study

USA300Δtet38farE::ΦNΕ

USA300Δtet38 recipient of farE::ΦNΕ
transposon insertion; Ermr

This study
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E. coli DH5α

Invitrogen

-

λ φ80dlacZΔM15Δ(lacZYA-argF)U169
recA1 endA1 hsdr17(rK- mK-) supE44 thi-1
gyrA relA1!
Plasmids:
pLI50

E. coli-S. aureus shuttle vector

pLIfarR!

pLI50 with native farR gene!

This study

pLIfarE
pGYlux

pLI50 with native farE gene
E. coli-S. aureus shuttle vector harboring
promoterless luxABCDE operon

This study
(37)

pCN51

pCN51c
pCN51farR
pKOR-1
pKORΔtet38

E. coli-S. aureus shuttle vector with Pcad
promoter for cadmium inducible gene
expression
pCN51, with ermC cassette replaced by
cat194 cassette from pRN7146
pCN51c with promoterless farR, for
cadmium inducible expression of farR
E. coli-S. aureus shuttle vector; contains
Pxyl/tetO; antisense secY RNA expression
pKOR-1 containing upstream and
downstream flanking sequences for deletion
of tet38
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(35)

(36)

This study
This study
(38)
This study

2.2.2(

Selection(and(comparative(genome(sequencing(of(fatty(acid(
resistant((FAR)(clones((

As reported previously, when an overnight culture of S. aureus USA300 was inoculated
into fresh TSB containing 50 µM linoleic acid, there was a 10-12h lag phase, followed by
unimpeded exponential growth (24). Therefore, to promote the selection of fatty acid
resistant clones, seven separate flasks of S. aureus USA300 were subjected to two
consecutive cycles of growth to stationary phase in TSB + 50 µM linoleic acid, after
which, samples of each culture were plated for isolation of single colonies. Colonies from
each plate were screened to identify fatty acid resistant (FAR) clones that could initiate
growth without a lag phase, when inoculated into TSB + 50 µM linoleic acid. A single
FAR clone was then selected from each of the seven separate biologic replicates, for
comparative genome sequencing. For controls, two single colonies of USA300 were
selected after two consecutive cycles of growth in TSB alone.
For comparative genome sequencing, genomic DNA was extracted from S. aureus using
previously described protocols (28, 29). All samples for comparative genome sequencing
were processed at the London Regional Genomics Centre (Robarts Research Institute,
London, Ontario, Canada; http://www.lrgc.ca) using the Ion Torrent Personal Genome
Machine (PGM) (Life Technologies, Carlsbad, CA) and 316 chips. Briefly, genomic
DNA was quantified using the Qubit and the Qubit dsDNA HS Assay (Life
Technologies, Carlsbad, CA). Samples then underwent fragmentation, adapter and
barcode ligation as per the Ion Xpress Fragment Library Kit (4469142 Rev. B), and size
selection using the Pippin Prep (Sage Science, Beverly, MA). The size of the final
libraries was verified using the Agilent 2100 Bioanalyzer and the High Sensitivity DNA
kit (Agilent Technologies Inc., Palo Alto, CA). Barcoded libraries were pooled at
equimolar concentrations, based on Qubit values, and the Template Dilution Factor
(TDF) for the final pooled library was calculated using molarity determined via qPCR,
with the Ion Library Quantification kit (4468802). Diluted libraries were processed as per
the Ion OneTouch Template Kit (4468007, Rev. B) for automated clonal amplification,
and sequenced using the Ion Express Template 200 kit (4474280), Enrichment Station
and the Ion Sequencing 200 Kit (4471999, Rev. B). Sequence reads were mapped to the

71

genome of S. aureus USA300 FPR3757 (30) using CLC Genomics Workbench 7.0
(Boston, MA), and automated detection of single nucleotide polymorphisms (SNPs) was
conducted using the Neighborhood Quality Standard algorithm (31).

2.2.3(

Strain(and(plasmid(construction(

Techniques for genetic manipulation of S. aureus were conducted according to
established guidelines (32), and as described in our previous work (24, 25, 33). The
University of Nebraska transposon mutant library (34) was used as a source of transposon
insertions that inactivated SAUSA300_2490 (NE1393) and SAUS300_2489 (NE2336).
These

were

transferred

into

plasmid

cured

USA300

strain

LAC,

creating

USA300farR::ΦNΕ and USA300farE::ΦNΕ respectively (Table 2.1). All recombinant
plasmids were first constructed as shuttle vectors in E. coli DH5α. The integrity of
plasmids isolated from E. coli were confirmed by restriction enzyme digestion, and
nucleotide sequencing of the cloned DNA fragments prior to electroporation into S.
aureus RN4220 as an intermediate host. From S. aureus RN4220, the individual plasmids
were then introduced, via electroporation into S. aureus USA300 or isogenic derivatives
as required. Primers used for PCR amplification of gene segments that were required for
plasmid construction are listed in Table 2.2.
Plasmid pLI50 (35) was used to complement mutations in SAUSA300_2490 (farR), and
SAUSA300_2489 (farE). To complement farE, a 2.8-kb fragment was amplified by PCR
of genomic DNA from S. aureus USA300 with forward and reverse primers farE_F1 and
farE_R1. Similarly, a 1.2-kb product containing the native farR gene was amplified with
primers farR_F1 and farR-R1. The PCR products were digested with KpnI and SacI, and
ligated into pLI50, which had been digested with the same enzymes. To construct
pCN51farR in which expression of farR is dependent on the cadmium inducible Pcad
promoter, we first excised the ermC cassette from pCN51 by digestion with AvrII and
XhoI, and replaced it with a 1.0 kb AvrII-XhoI fragment containing the cat194 cassette
from pRN7146 (36). The resulting pCN51c plasmid was then digested with BamHI and
AscI, and ligated to a 605 nt BamHI-AscI fragment containing the promoterless farR
gene, which was generated by PCR with primers CNfarR_F and CNfarR_R. To construct
pGYfarE::lux, in which expression of the luciferase operon is driven from the farE

72

promoter,

a

396

bp

fragment

containing

the

intergenic

segment

between

SAUSA300_2490 and SAUSA300_2489 (farE) was amplified with primers GYfarE_F
and GYfarE_R, and cloned into the BamHI and SalI sites of pGYlux (37).
A markerless in-frame deletion of tet38 (SAUSA300_0139), encoding a major facilitator
efflux pump, was constructed using pKOR-1, following established protocols (25, 38).
Briefly,

sequences

flanking

the

tet38 locus

were

amplified

by

PCR

using

primers tet38 5′F and tet38 5′R to generate the upstream arm, and primers tet38 3′F
and tet38 3′R to generate the downstream arm. The upstream and downstream flanking
arms were digested with SacII, ligated to one another, and then recombined into the
temperature-sensitive pKOR-1 vector, using attB1 and attB2 sites incorporated into the
flanking sequences by the respective tet38 5′F and tet38 3′R primers. The resulting
pKOR-1Δtet38 vector was first passaged through S. aureus RN4220 before being
introduced into USA300 by electroporation. The correct deletion of codons 42 through
439 of the tet38 gene was confirmed by PCR and DNA sequence analysis. The resulting
USA300Δtet38 strain was then used as a recipient for phage transduction, using
USA300farE::ΦNΕ as a donor (Table 2.1), to create USA300Δtet38- farE::ΦNΕ.
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Table 2.2 Primers used for construction of plasmids in Chapter 2.
a

Oligonucleotide
farE_F1b
farE_R1c
farR_F1b
farR_R1c
CNfarR_Fd
CNfarR_Re
GYfarE_Ff
GYfarE_Rg
tet38 5′Fh
tet38 5′Ri
tet38 3′Fi
tet38 3′Rj
a

Description

cccggtaccCACTTCCATGCAAAAAACCTCC
cccgagctcTGTACGGTGTACGAGTGCGTTG
cccggtaccTGCAGCTACAATCACTATCCATGC
cccgagctcACGGACGCTAAAACAGGTAGTCC
cccggatccgttaactaattaaCTACACACAAAGGAGAAATGTAG ATG
cccggcgcgccTGAATGTTGGTAACGCTCATGAG
cccggatccTTGTACGGTGTACGAGTGCG
cccgtcgacCGGTGCATTTGTAGCAAGTG
attB1-GAAACGGTTCTATTGCCAG
ggacctccgcggGTTTAAGTCATCAGCAATGGCTACAG
ggacctccgcggGTCAGCTTAAATCGTTGGACAC
attB2-CGCCACCTGATGCTTTTACTTCTAC

Lower case nucleotides indicate 5′-additions, to incorporate restriction endonuclease

sites for bKpnI, cSacI, dBamHI and stop codons (bold) in all three reading frames, eAscI,
f

BamHI, gSalI, hattB1 site GGGGACAAGTTTGTACAAAAAAGCAGGCT for cloning

in pKOR-1; iSacII site; jattB2 site GGGGACCACTTTGTACAAGAAAGCTGGGT for
cloning in pKOR-1.
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2.2.4(

Assay(of(growth(and(bactericidal(activity(

For growth and bactericidal assays, inoculum cultures were supplemented with antibiotic
where required, and these cultures were then inoculated into media that lacked antibiotics
to assess growth or bactericidal activity, in the presence of antimicrobial fatty acids. For
growth assays, flasks containing a 1:5 ratio of flask size to medium volume, and
supplemented with the indicated concentrations of fatty acid, were inoculated to an initial
OD600 of 0.01, and samples were withdrawn at hourly intervals for determination of
OD600. All cultures were grown in triplicate, or quadruplicate, as specified in individual
Figure Legends. For bactericidal assays, the overnight inoculum cultures were first subcultured into 25 mL of fresh TSB alone, to prepare non-induced cells, or TSB containing
20 µM sub-inhibitory fatty acid, to allow for induction of intrinsic resistance
mechanisms. After growth to mid-exponential phase (OD600 = 0.5), these inoculum
cultures were then inoculated into triplicate or quadruplicate flasks of fresh TSB (OD600 =
0.01; approximately 2x106 cfu/mL) containing a 100 µM bactericidal concentration of
fatty acid. The cultures were then incubated with shaking at 37°C, and aliquots were
withdrawn at hourly intervals for preparation of serial dilutions in sterile TSB.
Subsequently, 10 µl aliquots from each dilution were spotted in quadruplicate, on to TSB
agar plates, and colonies were counted after 24h of incubation. The mean of each
quadruplicate technical replicate was entered as a single data point for each flask, from
which the mean and standard deviation of the biologic replicate flasks was determined.

2.2.5(

Assay(for(uptake(of(14C0linoleic(acid(

Assays for growth and uptake of

14

C-linoleic acid were conducted according to

established protocol (39), with modifications, to evaluate the influence of farE on
accumulation of 14C-linoleic acid in S. aureus cells. Briefly, quadruplicate cultures of S.
aureus USA300 or isogenic USA300farE::ΦNΕ complemented with empty pLI50 vector,
or pLIfarE, were grown in TSB + 20 µM linoleic acid to an OD600 of approximately 0.3,
to allow for induction of farE. The cultures were then supplemented with an additional 50
µM dose of linoleic acid and returned to the shaker. After 30 minutes of exposure to 50
µM linoleic acid, aliquots were withdrawn, and supplemented with 0.2 µCi/mL of

14

C-

linoleic acid. Aliquots of 200 µL were then removed at intervals of 1, 2, 5, and 10
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minutes, and samples from each replicate were simultaneously filtered onto 0.45 µM
membrane filter discs using a vacuum manifold. The filters were then washed twice with
4 mL of 0.1 M phosphate buffer, pH 7.0 containing 1% Triton X-100, and after drying,
were placed in scintillation vials containing 4 mL of Cytoscint scintillation cocktail
(Fisher Scientific). Accumulated

14

C-linoleic acid was then quantified using a Beckman

LS 6500 scintillation system. Data are expressed as pMol of

14

C-linoleic acid

accumulated, per µg of total cell lysate protein in each sample.

2.2.6(

farE::lux,reporter(gene(assays(

Inoculum cultures harboring of pGYfarE::lux or pGYlux control plasmid were
subcultured into triplicate or quadruplicate flasks of TSB, or TSB supplemented with
different fatty acids, to achieve an initial OD600 = 0.01. The cultures were incubated at
37°C with orbital shaking, and samples were withdrawn at hourly intervals for OD600
determinations. For quantification of luminescence, 4 x 200-µL aliquots of each sample
were added to 96 well white opaque flat bottom plates (Greiner bio-one). After
supplementing each well with 20 µL of 0.1% vol/vol decanal in 40% ethanol,
luminescence measurements were immediately taken on a BioTek Synergy H4 Hybrid
Reader (BioTek; Winooski, VT) with 1 second of integration and a gain of 200. Data
values were recorded as relative light units (RLU), corrected for background by
subtraction of values recorded from cultures harbouring the empty pGYlux vector. The
data points were standardized for differences in growth by dividing RLU values with the
recorded OD600 of the cultures, when samples were withdrawn.

2.2.7(

Data(analyses(

Data points for growth, viability, and luciferase reporter gene assays were plotted and
analyzed using Graph Pad Prism v6.0f. Significant differences at specific time points
were determined by unpaired one-tailed Student’s t-tests.
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2.3( Results((
2.3.1(

Identification(of(single(nucleotide(polymorphism(in(linoleic(
acid(resistant(variants(of(S.,aureus,,

The preferred site of S. aureus colonization of humans is the anterior nares, where
concentrations of linoleic acid in nasal secretions can reach 40- to 50 µM (16). These
values correlate with our previous work, where 50 µM linoleic acid caused a 10-12h lag
phase in growth of USA300, followed by unimpeded exponential growth (24). Following
up on this, we observed that when stationary phase cells from a primary culture grown in
TSB + 50 µM linoleic acid were re-inoculated into the same medium, growth resumed
without a lag phase (Appendix 2). To determine if this was due to the selection of genetic
variants with increased resistance to linoleic acid, stationary phase cells from this second
culture were plated on TSB agar for selection of single colonies. From these, we
identified several that could initiate growth without a lag phase, when inoculated into
TSB + 50 µM linoleic acid. Seven such fatty acid resistant (FAR) clones were subjected
to comparative genome sequencing, and two of these, designated FAR6 and FAR7, had
an identical single nucleotide polymorphism (SNP); a C>T transition that alters the H121
codon (CAT) to Y (TAT) in a putative transcriptional regulator encoded by
SAUSA300_2490 (30). FAR6 had a second SNP in a pyruvate oxidase encoded by cidC.
Therefore, we focused on FAR7, which had just one SNP in SAUSA300_2490, and resequencing of this gene in USA300 and FAR7 confirmed the unique SNP in FAR7.

2.3.2(
We

Description(of(the(farE4farR(locus(,

hypothesize

that

SAUSA300_2490,

and

a

divergently

transcribed

gene

SAUSA300_2489, respectively comprise a regulator and effector gene pair that we have
designated as farR and farE, to denote predicted functions as a regulator and effector of
fatty acid resistance. These assignments are supported by bioinformatics analyses. farR
encodes a 182 amino acid protein, with an N-terminal TetR family DNA binding domain
(2.33e-04), and overall similarity to the AcrR cluster of orthologous groups of proteins
(6.52e-09). In Gram-negative bacteria, AcrR regulators control expression of efflux pumps
belonging to the AcrB family, which are often encoded by divergently transcribed genes,
as with acrR-acrABC in E. coli (40) and orthologous mtrR-mtrCDE arrangement in N.
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gonorrhoeae (41). Similarly, farE is divergently transcribed from farR and encodes an
822 amino acid protein that is annotated as a drug exporter of the resistance-nodulationdivision (RND) superfamily (30), to which AcrB and orthologous efflux pumps are also
assigned (42). Genome annotation also assigns FarE to the MMPL family of proteins, on
the basis of homology to large membrane proteins of Mycobacterium tuberculosis, that
transport mycolic acids to the cell surface (43). Using protein structural modeling
programs HHPRED and PHYRE2 (44, 45), FarR was predicted with greater than 99%
confidence, to resemble known AcrR family regulators, including PfmR and FadR of
Thermus thermophilus, which control expression of genes involved in fatty acid synthesis
and metabolism (46, 47), and MtrR; an efflux pump regulator of Neisseria gonorrhoeae
(41, 48). Likewise, 80% of the FarE amino acid sequence was modeled with 100%
confidence, on the structure of AcrB from E. coli (49).

2.3.3(

farR(is(required(for(inducible(resistance(to(linoleic(acid(

We hypothesized that farR should regulate expression of farE in response to
antimicrobial fatty acids, which was addressed by constructing a farE::lux reporter,
where expression of the lux operon is under transcriptional control of the farE promoter.
When USA300-pGYfarE::lux was cultured in TSB, there was a modest peak of
luciferase activity in early exponential growth, which quickly dissipated (Fig. 2.1).
However, in TSB + 20 µM linoleic acid, luciferase activity was strongly induced in early
exponential phase cells, and again dissipated as the cells progressed towards stationary
phase. Importantly, no induction was observed in USA300farR::ΦNΕ cells. Although
USA300farR appeared to exhibit superior growth to wild type USA300 in TSB + 20 µM
linoleic acid (Fig. 2.1), our further analysis on this phenomenon uncovered that it reflects
a growth penalty that is imposed on USA300 by forced expression of the luxABCDE
genes. This was evident from a growth comparison of USA300 harboring either
pGYfarE::lux or empty pGYlux, in TSB + 20 µM linoleic acid, where cells carrying
pGYfarE::lux exhibited significantly slower growth compared to USA300 with empty
vector (Appendix 3).
These assays suggested that USA300 should exhibit inducible resistance to the
antimicrobial activity of linoleic acid. It was previously reported that exponential phase
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cells of S. aureus were significantly more sensitive to the bactericidal activity of
antimicrobial fatty acids, relative to stationary phase cells (17), which we confirmed in a
preliminary experiment (Appendix 4). Therefore, to assess inducible resistance, USA300
and USA300farR::ΦNΕ were grown to mid-exponential phase in TSB (non-induced), or
TSB + 20 µM linoleic acid (induced), and then diluted to 106 cfu/mL in fresh TSB
containing 100 µM linoleic acid. Non-induced USA300 suffered a > 3-log loss of
viability after 1h of exposure to 100 µM linoleic acid (Fig. 2.2A), while the induced cells
retained significantly greater viability at all time points, such that there was only an
approximate

40-fold

loss

of

viability

after

5h.

Furthermore,

the

induced

USA300farR::ΦNΕ cells exhibited a significantly greater loss of viability compared to
induced USA300, after 2h and onwards. Although the induced USA300farR::ΦNΕ cells
initially retained significantly greater viability compared to non-induced USA300, they
exhibited a progressive loss of viability, such that after 4h of exposure, the remaining
viable cells did not significantly differ from non-induced USA300 cells.
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0.01

0
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2
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Time (h)

6

0.001

USA300; TSB
USA300; TSB + 20 LA
USA300farR::ΦΝΕ; TSB
USA300farR::ΦΝΕ; TSB + 20 µM LA
Figure 2.1 Linoleic acid induces expression of farE. Growth (OD600; open symbols)
and relative luminescence units (RLU/OD; closed symbols) of USA300 and
USA300farR::ΦNΕ, harboring the pGYfarE::lux reporter vector, are charted. USA300
was grown in TSB or TSB + 20 µM linoleic acid (LA); USA300farR::ΦNΕ was grown in
TSB or TSB + 20 µM linoleic acid. Each value represents the mean and standard
deviation of three separate cultures, and each culture was subjected to quadruplicate
luminescence readings at each time point.
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Viability in 100 µM linoleic acid
A.

B.
107
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Induced USA300 vs farR::ΦΝΕ:
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*
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Time (h)

USA300farR::ΦΝΕ + pLI50; TSB + 20 µM LA
USA300farR::ΦΝΕ + pLIfarR; TSB + 20 µM LA

USA300; TSB
USA300; TSB + 20 LA
USA300farR::ΦΝΕ; TSB + 20 µM LA

Figure 2.2 Sensitivity of USA300 and USA300farR::ΦNΕ to the bactericidal activity
of 100 µM linoleic acid. A. USA300 or USA300farR::ΦNΕ challenge cells were grown
to mid-exponential phase in TSB or TSB + 20 µM linoleic acid and then diluted to 106
cfu/mL in TSB containing 100 µM linoleic acid, followed by monitoring of viability at
hourly intervals. B. USA300farR::ΦNΕ was complemented with empty pLI50 vector or
pLIfarR and assayed for viability in 100 µM linoleic acid, after initial growth in TSB +
20 µM linoleic aicd. All data points represent the mean ± standard deviation, of viability
determinations from quadruplicate cultures. Significant differences in viability at each
time point were determined by unpaired one-tailed Student’s t-test; ***, P < 0.001; **, P
< 0.01; *, P < 0.05; ns, nonsignificant.
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To validate a role for farR, USA300farR::ΦNΕ was complemented with empty pLI50, or
pLIfarR harboring farR and its native promoter, to determine whether pLIfarR could
restore inducible resistance. Accordingly, when pre-induced by growth in 20 µM linoleic
acid, USA300farR::ΦΝΕ + pLIfarR retained significantly greater viability after 2h of
exposure to 100 µM linoleic acid, compared to USA300farR::ΦΝΕ + pLI50 (Fig. 2.2B).
Nevertheless, pLIfarR did not appear to restore the level of inducible resistance to that of
wild type USA300, which retained approximately 105 cfu/mL viable cells after 5h of
exposure (Fig. 2.2A). We reasoned that this could be due to two variables; first, that farR
might be expressed at a high level from its native promoter on a multi-copy plasmid, and
second, that the FarR protein could engage nucleotide sequences on pLIfarR, which
contained the entire farE-farR intergenic segment, and these in trans interactions could
limit the ability of FarR to regulate farE on the chromosome. To overcome these
limitations, we expressed farR using the cadmium inducible Pcad promoter, and observed
an approximate 100-fold difference in viability when USA300farR::ΦΝΕ + pCNfarR
cells were exposed to 100 µM linoleic acid, in the presence or absence of 10 µM
cadmium (Appendix 5). Cumulatively, these data support the contention that farR is
required to manifest an inducible resistance phenotype in S. aureus USA300.

2.3.4(

farE,contributes(to(persistence(and(growth(of(S.,aureus,in(
the(presence(of(linoleic(acid(

We previously established that USA300 could grow in TSB containing 25 µM linoleic
acid, whereas 50 µM linoleic acid imposed a 10-12h lag phase. Our current reporter gene
assays also established that farE was induced by growth in TSB containing 20 µM
linoleic acid. Therefore, we expected that farE would be required to support growth of S.
aureus USA300 at a 25 µM upper threshold of linoleic acid, and that induction of farE
would confer protection against challenge of S. aureus with a 100 µM bactericidal
concentration. To address the growth requirement, USA300 or USA300farE::ΦNΕ were
cultured in TSB containing 5, 10, 20, or 25 µM linoleic acid. USA300 was not adversely
affected by 5- or 10 µM linoleic acid, but exhibited slower growth in 20- or 25 µM
linoleic acid (Fig. 2.3A). Comparatively, USA300farE::ΦNΕ exhibited similar behavior
at 5, 10 and 20 µM linoleic acid, but was unable to initiate growth over an 8h incubation
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in 25 µM linoleic acid (Fig. 2.3B). Furthermore, when USA300farE::ΦNΕ was
complemented with pLIfarE, we observed growth restoration not only in 25 µM linoleic
acid (Fig. 2.3B), but also in up to 100 µM linoleic acid (Fig. 2.3C); compare this to wild
type USA300, which was unable to grow in 50 µM linoleic acid (Fig. 2.3C).
To ensure that the role of farE was not dependent on factors that are uniquely associated
with the CA-MRSA strain USA300 genetic background, we transduced farE::ΦNΕ into
S. aureus SH1000, which is a methicillin susceptible laboratory strain that has the same
multi-locus sequence type (MLST) as USA300 (50). Although SH1000 exhibited
somewhat greater intrinsic resistance to linoleic acid, as evident from its ability to grow
in TSB + 50 µM linoleic acid, SH1000farE::ΦNΕ exhibited an extended lag phase, with
no obvious growth over 6h (Fig. 2.3D). Therefore, farE promotes growth of both MRSA
and MSSA strains at elevated concentrations of linoleic acid.
To evaluate the role of farE in promoting inducible resistance, USA300 and
USA300farE::ΦNΕ were grown in TSB alone, or TSB containing 20 µM linoleic acid,
prior to subculture into 100 µM linoleic acid (Fig. 2.4). Consistent with farE not being
appreciably

expressed

in

non-induced

cells,

the

non-induced

USA300

and

USA300farE::ΦNΕ cultures both suffered a rapid loss of viability on exposure to 100 µM
linoleic acid. However, when the cells were grown under inducing conditions prior to
challenge with 100 µM linoleic acid, USA300 exhibited only a 10- to 40-fold loss of
viability over 5h, and retained significantly greater viability at all time points, compared
to USA300farE::ΦNΕ. Interestingly, the induced USA300farE::ΦNΕ challenge cells still
retained significantly greater viability compared to non-induced USA300, which suggests
that factors in addition to farE may also promote inducible resistance. Cumulatively,
these data confirm that farE contributes to the inducible resistance of S. aureus to the
bactericidal activity of 100 µM linoleic acid, and is also required to support growth in as
low as 25 µM linoleic acid. It further appears that resistance is proportional to farE
expression, as suggested by the ability of pLIfarE to support growth of
USA300farE::ΦNΕ at concentrations of linoleic acid that could not be tolerated by
USA300 (Fig. 2.3C).
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Figure 2.3 Mutation of farE::ΦNΕ enhances sensitivity of S. aureus to toxicity of
linoleic acid. Growth of USA300 (A) or USA300farE::ΦNΕ (B) in TSB supplemented
with 5 µM, 10 µM, 20 µM or 25 µM linoleic acid, and that of USA300farE::ΦNΕ +
pLIfarE in TSB + 25 µM linoleic acid. C. Growth of USA300 or USA300farE::ΦNΕ in
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µM linoleic acid. D. Growth of S. aureus SH1000 or SH1000 farE::ΦNΕ in TSB + 50
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quadruplicate (B) cultures.
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2.3.5%

The%FAR7%clone%exhibits%increased%expression%of%farE%%

FAR7 is distinguished from USA300 by a SNP in farR that changes H121 to Y in the gene
product. This clone was selected for its ability to grow without a lag phase in TSB + 50
µM linoleic acid, and our data suggest that this should be due to increased expression of
farE, as a consequence of the SNP in farR. This was confirmed by conducting farE::lux
reporter gene assays, in both USA300 and FAR7 (Fig. 2.5). When grown in TSB, FAR7
exhibited significantly greater luciferase activity compared to USA300, and during
growth in TSB + 20 µM linoleic acid, the luciferase activity in FAR7 significantly
exceeded that of USA300. Therefore, the SNP that causes a H121Y substitution in FarR
results in a constitutive level of farE expression during growth in TSB, and permits a
significantly greater induced level of expression, than could otherwise be achieved in
USA300.

2.3.6%

An%H121Y%substitution%in%FarR%is%sufficient%for%increased%
resistance%to%linoleic%acid%

Since USA300 and FAR7 are differentiated on the basis of a SNP that causes a H121Y
substitution in FarR, we expected that this alone would be sufficient to promote increased
resistance to linoleic acid. Accordingly, although FAR7 and USA300 exhibited no
difference in growth when cultured in TSB, FAR7 was uniquely able to grow in TSB +
100 µM linoleic acid (Fig. 2.6A). In bactericidal assays, non-induced USA300 and FAR7
both suffered a similar rapid loss of viability when exposed to 100 µM linoleic acid (Fig.
2.6B). Therefore, although there is some constitutive expression of farE during growth of
FAR7 in TSB, this is not sufficient to promote resistance to 100 µM linoleic acid.
However, when the assay was conducted with cells grown under inducing conditions,
FAR7 did not exhibit any significant loss of viability over 5h of exposure to 100 µM
linoleic acid, and exhibited significantly greater retention of viability from 3- to 5h,
compared to USA300 (Fig. 2.6B). These observations are consistent with our farE::lux
assays, where FAR7 exhibited a significantly higher induced level of farE expression
compared to USA300, and support the contention that increased expression of farE
correlates with increased resistance.
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To further define the impact of the H121Y substitution, USA300farR::ΦNΕ was
transformed with pLI50 harboring wild type farR, or the variant farR7 allele derived from
FAR7. With no complementation, USA300farR::ΦNΕ exhibited no growth over an 8h
incubation in TSB + 50 µM linoleic acid, and cells complemented with wild type pLIfarR
were also unable to grow (Fig. 2.7). However, cells complemented with the variant farR7
allele acquired the ability to grow in 50 µM linoleic acid, and also at a reduced rate in
100 µM linoleic acid. Therefore, a SNP that introduces a H121Y substitution in FarR is
alone sufficient to confer increased resistance of S. aureus towards linoleic acid,
presumably due to increased expression of farE.

2.3.7%

Role%of%farE%in%resistance%to%other%uFFA%

Although farE is induced by and promotes resistance to linoleic acid, S. aureus would be
exposed to a varying diversity and abundance of free fatty acids, dependent on the
context within the human body. In a tissue abscess, pus contains high concentrations of
unsaturated free fatty acids, which could be derived from triglyceride (18, 51), or human
cell membrane phospholipid, where the major unsaturated fatty acids, oleic (C18:1),
linoleic (C18:2), and arachidonic acid (C20:4), each comprise approximately 13- to 15%
of the total fatty acid content (22, 23). Conversely, although sapienic acid or its isomer
palmitoleic acid (C16:1) do not comprise a major proportion of the fatty acid profile of
phospholipid, sapienic acid is the major unsaturated fatty acid in human sebum, both as
free fatty acid, and in sebum triglyceride (14, 52). Therefore, to better understand the
biological role of farE, we evaluated the specificity of farE induction by these different
fatty acids, and the extent to which farE confers resistance to other fatty acids.
To evaluate the specificity of induction, USA300-pGYfarE::lux was grown to an OD600
of ~ 0.5 in TSB, or TSB supplemented with 20 µM fatty acid, followed by assay of
luciferase activity (Fig. 2.8A). There were significant differences in the ability of
different 18-carbon chain length fatty acids to induce farE::lux, such that no induction
was observed with saturated stearic acid (C18:0), or oleic acid (C18:1), while linoleic
acid (C18:2) was a strong inducer. Strikingly, arachidonic acid (C20:4) promoted a
significantly higher level of expression compared to linoleic acid, while linolenic acid
(C18:3), together with palmitoleic acid (C16:1) and its isomer sapienic acid, each
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facilitated an intermediate level of expression, which was significantly greater than that
of TSB alone, but significantly less than that of linoleic and arachidonic acid.
Consistent with the modest induction by 20 µM palmitoleic acid, when a bactericidal
assay was conducted with USA300 and USA300farE::ΦNΕ cells that were pre-induced
by growth in 20 µM palmitoleic acid, there were no significant differences in retention of
viability after exposure to 100 µM palmitoleic acid (Fig. 2.8B). However, when this
assay was performed with arachidonic acid, USA300 retained significantly greater
viability after 2h of exposure, compared to USA300farE::ΦNΕ (Fig. 2.8B). Therefore,
farE appears to have a primary role in mediating resistance to linoleic- and arachidonic
acid, which are the most effective inducers of farE expression.
Although farE did not promote resistance to palmitoleic acid, we nevertheless observed a
significant induction of expression by 20 µM palmitoleic acid (Fig. 2.8A), in addition to
which, FAR7 was able to grow in TSB containing 50 µM palmitoleic acid, whereas
USA300 could not (Appendix 6). This suggested that farE could still promote resistance
to palmitoleic acid, if expressed at a sufficiently high level. Furthermore, it was recently
reported that tet38, which encodes a major facilitator superfamily efflux pump, was
induced by palmitoleic acid and contributed to resistance (21). Therefore, we considered
that one efflux pump might compensate for loss of another, which could obfuscate the
phenotype of USA300farE::ΦNΕ when tested with palmitoleic acid. To address this, we
constructed a markerless Δtet38 mutation in USA300, which was assayed for growth in
TSB + 25 µM or 40 µM palmitoleic acid. The higher concentration imposed a slower
growth rate, as evident from a time of 5h being required for USA300 to achieve an OD600
= 0.5, compared to approximately 3h in 25 µM palmitoleic acid (Fig. 2.9). Nevertheless,
there were no discernible differences in growth between USA300, and the individual
USA300Δtet38 or USA300 farE::ΦNΕ mutants, or combined USA300Δtet38-farE::ΦNΕ
double mutant. Therefore, neither farE nor tet38 exerted a significant impact on
resistance to palmitoleic acid under the conditions that we have tested.
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Figure 2.8 Influence of different antimicrobial fatty acids on induction of farE, or
viability of S. aureus USA300 and USA300farE::ΦNΕ. A. Quantification of
pGYlux::farE dependent luciferase activity in S. aureus USA300 grown to OD600 = 0.5 in
TSB alone, or TSB supplemented with 20 µM of fatty acid, as indicated. Each value
represents the mean of quadruplicate measurements, from each of four replicate cultures.
P values indicate significant differences compared to growth in TSB alone, or significant
difference between linoleic and arachidonic acid. B. Bactericidal activity of 100 µM
linoleic acid (C18:2), arachidonic acid (C20:4), or palmitoleic acid (C16:1) towards
USA300 or USA300farE::ΦNΕ cells. The inoculum cultures were grown to OD600 = 0.5
in TSB supplemented with 20 µM of the respective fatty acids, prior to challenge with a
100 µM bactericidal concentration. Asterisks indicate P-values of significant differences
between USA300 and USA300farE::ΦNΕ. Each value represents the mean of viability
determination from quadruplicate cultures. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns,
nonsignificant.
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Figure 2.9 Effect of farE::ΦNΕ and Δtet38 mutations on growth of S. aureus in the
presence of 25 µM or 40 µM palmitoleic acid (PA). USA300, USA300farE::ΦNΕ,
USA300Δtet38, and USA300Δtet38-farE::ΦNΕ were grown in TSB supplemented with
25 µM or 40 µM palmitoleic acid (PA), as indicated. The dotted line with arrow depicts
the time of growth at which OD600 = 0.5.
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2.3.8%

Inactivation%of%farE%promotes%increased%uptake%of%14CGlinoleic%
acid%

Although many bacteria can derive energy from exogenous fatty acids through an
inducible β-oxidation pathway (53), S. aureus lacks this ability, and its primary means of
coping with exogenous fatty acids is through incorporation into phospholipid (19, 39, 54,
55). Since our data suggest that FarE promotes efflux of fatty acids, we expected that
inactivation of farE would promote increased uptake of exogenous fatty acid. Prior to
quantifying uptake of 14C-linoleic acid, we first conducted a mock assay, to evaluate the
ability USA300 and USA300farE::ΦNΕ to recover from exposure to an abrupt increase
in the concentration of linoleic acid. Cultures were grown to OD600 = 0.3 in TSB
supplemented with sub-inhibitory 20 µM linoleic acid, to allow for induction of farE in
USA300, and the cells were then challenged with a 50 µM dose of linoleic acid, followed
by monitoring of OD600. After 30 minutes, each of USA300, USA300farE::ΦNΕ +
pLI50, and USA300farE::ΦNΕ+ pLIfarE exhibited evidence of continued growth (Fig.
2.10A). However, beyond 30 minutes, growth of USA300farE::ΦNΕ+ pLI50 was
severely impaired, whereas USA300 continued to grow, and USA300farE::ΦNΕ+
pLIfarE exhibited superior recovery. These data confirm that farE contributes to the
ability of S. aureus USA300 to recover from an abrupt increase in the concentration of
exogenous linoleic acid, and that conditions of the assay were not bactericidal.
We next wished to address the question of whether FarE was responsible for actively
extruding linoleic acid from the S. aureus cell. To do this, we performed uptake assays
using 14C-linoleic acid. We performed these assays on cells that were treated the same as
for the growth experiments described in Figure 2.10A, and cultures were supplemented
with

14

C-linoleic acid, 30 minutes after challenge with 50 µM linoleic acid. Strikingly,

USA300farE::ΦNΕ complemented with pLIfarE exhibited the least accumulation of 14Clinoleic acid, while USA300farE::ΦNΕ harboring the empty pLI50 vector exhibited the
greatest accumulation, and wild type USA300 exhibited intermediate accumulation (Fig.
2.10B). Importantly, this reflected an inverse correlation between recovery of growth
after exposure to 50 µM linoleic acid, and accumulation of 14C-linoleic acid. Specifically,
USA300farE::ΦNΕ + pLIfarE exhibited the least accumulation of 14C-linoleic acid, and
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its growth was not adversely affected, whereas USA300farE::ΦNΕ + pLI50 exhibited the
greatest accumulation and its growth was severely impaired, while wild type USA300
exhibited intermediate growth and accumulation kinetics. These data support the
contention that FarE mediated efflux of unsaturated free fatty acids is required to support
growth of S. aureus at elevated concentrations of antimicrobial fatty acid.

97

Growth Assay

1

0

1

2

Time (h)

3

4

pmol/ug

OD600

Add 50 µM LA
Add 14C-LA

0.1

Uptake Assay

B.
14C-Linoleic Acid

A.

3
2
1
0

4

0

2

4

6

8

10

Time (m)

USA300
USA300farE::ΦNE + pLI50
USA300farE::ΦNE+ pLI-farE

USA300
USA300farE::ΦNE + pLI50
USA300farE::ΦNE+ pLI-farE

Figure 2.10 Growth (A) and uptake of 14C-linoleic acid (B) following exposure of S.
aureus USA300 and USA300farE::ΦΝΕ to an increase in concentration of linoleic
acid. A. quadruplicate cultures of USA300, USA300farE::ΦΝΕ + pLI50, or
USA300farE::ΦΝΕ + pLIfarE were grown in TSB + 20 µM linoleic acid to an OD600 of
approximately 0.2 to 0.3. The cultures were then supplemented with an additional 50 µM
dose of linoleic acid, and growth (OD600) was measured after 30 minutes, and then at
hourly intervals. When this experiment was conducted for the purpose of quantifying
uptake of 14C-linoleic acid (B), the cultures were supplemented with 0.20 µCi/mL of 14Clinoleic acid at t = 30 minutes, and aliquots of culture were processed for quantification
of

14

C-linoleic acid uptake at intervals of 1, 2, 5, and 10 minutes. Each data point

represents the mean and standard deviation of quadruplicate samples.
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2.4% Discussion%%
Through comparative genome sequencing of S. aureus USA300 variants that were
selected for enhanced resistance to linoleic acid, we identified a regulator of fatty acid
resistance, farR, and an effector of fatty acid resistance farE, which to our knowledge, is
the first description of a dedicated and inducible mechanism of S. aureus resistance to
antimicrobial fatty acids. These genes bear a similarity to the acrR and acrB paradigm in
E. coli, where acrR and acrB were discovered through in vitro selection of acriflavineresistant mutants, which mapped to the acr locus (40, 56, 57). The emergence of
antibiotic resistance in Gram-negative bacteria has also been attributed to the in vivo
selection of mutations in the transcriptional repressor acrR, which promote increased
expression of the efflux pump encoded by acrB (58-60). Similarly, we discovered farR
through in vitro selection of USA300 variants with increased resistance to linoleic acid.
As with many proteins that possess an N-terminal TetR DNA binding domain, protein
structural modeling and homology searches indicate that FarR belongs to the TetR/AcrR
family of regulators, while FarE belongs to the RND-family of multi-drug efflux pumps,
which include AcrB.
In addition to our own work which support a role for FarE as an efflux pump, other
researchers using a different approach with S. aureus COL, demonstrated that an amino
acid substitution in FarE (SACOL2566) promotes resistance to a newly described
oxadiazole family of antibiotics (61). In E. coli, polymorphisms that cause amino acid
substitutions in AcrB can also accrue during in vitro selection of strains that are resistant
to fluoroquinolone antibiotics (62), and in these examples, it is likely that resistance is
due to amino acid substitutions that expand the substrate specificity of the efflux pump
(61, 62). However, although AcrB family efflux pumps have been most extensively
characterized as mediators of multiple drug resistance, we contend that the primary
function of FarE is to promote efflux of antimicrobial fatty acids that would be
encountered during colonization, or within a tissue abscess. This is consistent with the
belief that members of the AcrB family, which are encoded by the core genome, evolved
to promote efflux of host-derived toxic compounds, including bile salts and fatty acids
(63-68).
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It is especially significant that expression of farE was most strongly induced by linoleic
and arachidonic acid. Since S. aureus cannot synthesize unsaturated fatty acids (69), our
data suggest that farE is induced as part of a signaling pathway that is activated by hostspecific unsaturated free fatty acids. In other work, bactericidal assays conducted with
human nasal secretions established that cholesterol esters of linoleic- and arachidonic
acid were the principal bactericidal components towards Pseudomonas aeruginosa,
which does not colonize the nose, but did not affect viability of S. aureus (16), and
linoleic acid is also the principal antimicrobial fatty acid in homogenates of murine tissue
abscesses (18, 51). Although arachidonic acid was not identified as a major fatty acid in
abscess homogenates, it is a major unsaturated fatty acid in erythrocyte and leukocyte
membrane phospholipid (23, 70), from which it is released by phospholipases at sites of
infection, and rapidly converted to inflammatory mediators (71). Therefore, the induction
of farE in response to linoleic- and arachidonic acid may represent an evolutionary
feature that contributes to the success of S. aureus as a human pathogen.
Our observations are consistent with a requirement for FarE in maintaining membrane
homeostasis when S. aureus is exposed to host-derived antimicrobial unsaturated free
fatty acids. Since S. aureus cannot degrade exogenous fatty acids through β-oxidation, its
primary means of coping with exogenous fatty acids is through incorporation into
membrane phospholipid, which involves a novel fatty acid kinase pathway, whereby
phosphorylated fatty acid is directly incorporated into glycerol-3-phosphate (54, 55). This
in itself may represent a primary means of detoxifying long chain unsaturated free fatty
acids, which promote loss of membrane integrity and cell death if allowed to accumulate
in the cytoplasmic membrane (19). Importantly, S. aureus cannot synthesize unsaturated
fatty acids, and maintains membrane fluidity through synthesis of branched chain fatty
acids; primarily anteiso-C15 (69). From these considerations, we can envision two
scenarios whereby FarE would be required under such conditions.
First, although some bacteria cease the de novo synthesis of fatty acids when provided
with an exogenous supply of unsaturated fatty acids, this does not occur in S. aureus,
which continues to synthesize fatty acids (72). However, under such conditions, there is
reduced incorporation of endogenously synthesized anteiso-C15 into phospholipid, likely
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due to displacement or competition from the exogenous unsaturated fatty acid (72, 73).
Consequently, it is likely that unutilized metabolites will accumulate, which could be
dealt with through an efflux mechanism, and at least one study has proposed that the
primary function of an RND family efflux pump is to promote efflux of fatty acids that
are replaced as a result of membrane damage or phospholipid turnover (74). Second,
although incorporation of unsaturated fatty acids into phospholipid may comprise an
effective means of detoxification, it would also promote an increase in membrane fluidity
which if too severe, would compromise membrane function. In this context, we note from
our analysis of uptake of

14

C-linoleic acid, that USA300farE::ΦNΕ cells exhibited

significantly greater uptake of

14

C-linoleic acid compared to wild type USA300 (Fig.

2.10B). Therefore, although growth of USA300farE::ΦNΕ cells was impaired under
these conditions (Fig. 2.10A), it continued to accumulate

14

C-linoleic acid, which

suggests that there is sufficient metabolic capacity to incorporate unsaturated fatty acid
into phospholipid, at a level that is beyond the tolerance for proper membrane function.
Consequently, FarE function could also be required under such conditions, to ensure that
incorporation of unsaturated fatty acid into phospholipid does not exceed a level of
tolerance for membrane fluidity.
Although our data supported a role for farE in mediating resistance to linoleic and
arachidonic acid, it did not confer resistance to palmitoleic acid, which is consistent with
their being distinct mechanisms for resistance to unsaturated fatty acids of 16- and 18carbon chain length. First, S. aureus exhibits a differential capacity to incorporate
exogenous unsaturated 16- or 18-carbon fatty acids into membrane phospholipid. Oleic
acid (C18:1) is directly incorporated into phospholipid (72), but palmitoleic acid must
first be extended by the S. aureus fatty acid biosynthesis machinery, in a rate limiting
step, to produce C18:1, which is then incorporated into phospholipid (19). Perhaps due to
the less efficient incorporation of C16:1 fatty acids into phospholipid, S. aureus has
evolved some capacity to exclude entry of palmitoleic and sapienic acid into the
cytoplasm, due to cell surface teichoic acids and the low iron-induced cell surface protein
IsdA, which function as a filtering mechanism to restrict penetration through the cell wall
(19, 20). Others also reported that a major facilitator superfamily efflux pump encoded by
tet38 promoted resistance to palmitoleic acid (21), and although we were not able to
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confirm this through construction of a USA300Δtet38 deletion mutant, it may be that
tet38 functions in a strain specific context.
Further relevant to these considerations, expression of tet38 was induced primarily by
palmitoleic acid, and much less effectively by linoleic acid, whereas we observed the
opposite response for induction of farE. Importantly, with our identification of a SNP in
farR that promotes increased expression of farE, we have provided the first mechanistic
description of an efflux pump that is specifically induced in response to antimicrobial
fatty acids in S. aureus, and at a broader level, in Gram-positive bacteria. FarR belongs to
the TetR/AcrR family of transcriptional regulators, which usually repress transcription of
divergent genes, by virtue of an N-terminal DNA binding domain that recognizes a
specific operator site in the promoter segment of a target gene, and the affinity of this
interaction is modulated by a C-terminal domain that binds a small inducing ligand (75,
76). In a relevant example, FadR of Thermus thermophilus represses expression of genes
required to degrade fatty acids, which are de-repressed upon binding of an acyl-CoA
ligand to FadR (46). However, although farE is induced by antimicrobial fatty acids, we
cannot yet conclude that farR is alone sufficient to regulate farE. If FarR functioned
strictly as a repressor, then inactivation of farR should have caused de-repression of farE.
However, this was not observed, and farR was in fact needed for induction of farE (Fig.
2.1). Conversely, FAR7 exhibited a constitutive measure of farE expression, attributed to
the H121Y substitution in FarR, which also conferred a significantly higher induced level
of farE expression than could be achieved in wild type USA300 (Fig. 2.8B).
As this substitution is not within the N-terminal DNA binding domain, which spans
amino acids 28-61 of FarR, it should not directly affect the DNA binding function.
However, in a potentially related example, FadR represses expression of genes required
for β-oxidation of fatty acids, and the conformation of amino acids 106-119 in the Cterminal domain underwent a significant shift on binding of fatty acid, including R109,
which had an important role in maintaining the DNA-binding affinity, even though it is
not within the N-terminal DNA binding domain (77). Therefore, the H121Y substitution in
FarR could still affect the function of the N-terminal DNA binding domain, or alternately
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it may affect the ability of FarR to form functional oligomers; typically dimers or
tetramers, which is another characteristic trait of the TetR family of regulators (75, 78).
Although most TetR regulators repress expression of divergently transcribed genes (75,
78), our observation that FarR is required for induction of farE is not unprecedented, and
FarR may resemble a limited number of TetR regulators that trigger a broader cellular
response to environmental insults (78-83). In one such example, the SczA metal iondependent transcriptional regulator of Streptococcus pneumoniae (82) binds to a specific
operator site to repress transcription of a target gene in the absence of zinc, but when zinc
is present, it binds to a different DNA segment upstream of the regulated gene to activate
transcription. Alternatively, FarR may still function as repressor of farE in the absence of
inducer, and then in the presence of exogenous fatty acid may serve to promote
expression of a positive acting transcription factor that is needed to activate farE. This
would partially conform to the AcrR-AcrB paradigm, where AcrR ensures that acrB is
not expressed in the absence of an inducing stimulus, but other positive acting factors are
required to activate acrB (84-86). With these considerations in mind, work is in progress
to determine the mechanism of FarR-dependent regulation of gene expression, through
analysis of its interaction with different fatty acids and target promoters, and the scope of
genes that are affected by this interaction.
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3.1% Introduction%
Methicillin-resistant Staphylococcus aureus has rapidly achieved pandemic status in
community and hospital settings. To persist on human hosts, S. aureus must have
intrinsic defense mechanisms to cope with antimicrobial unsaturated free fatty acids
(uFFA), an important component of human innate defense mechanisms. In previous
work, we identified a regulator of fatty acid resistance, FarR, which belongs to the TetR
family of transcriptional regulators (TFR) (1). TFRs represent the third most ubiquitous
transcriptional regulators in prokaryotes (2). This family is named after the prototypic
TetR that has a role in mediating tetracycline resistance (3). Members of this family
typically exert their effect on divergent genes in response to small hydrophobic ligands
and are involved in the transcriptional regulation of a wide range of biological functions
such as multidrug resistance, antibiotics biosynthesis, quorum sensing, and pathogenicity
(4). Studies show that overexpression of multidrug efflux pumps, and the resulting
antibiotic resistance, is often attributed to mutations in transcriptional regulators such as
those belonging to the TetR family. In Gram-negative bacteria, AcrAB is an RND-efflux
pump regulated by the TFR, AcrR, and other global transcriptional regulators such as
MarA, SdiA, RobA and SoxS (5, 6). In this paradigm, the de-repression of AcrR in the
presence of an inducing ligand is not enough to ensure that the pump is only expressed
when needed, and additional positive-acting factors are needed to fully activate the efflux
pump (7). As a result the TFR AcrR fine-tunes the expression of the efflux pump, as
opposed to straightforward repression and de-repression (8). Nevertheless, mutations in
acrR alone can cause overexpression of the AcrAB efflux pump and are linked to
antibiotic resistance in clinical isolates (9). Similar to the acrR and acrB paradigm in E.
coli, where acrR and acrB were discovered by in vitro selection of acriflavine-resistant
mutants, we discovered farR through in vitro selection of USA300 variants with
increased resistance to linoleic acid (1).
Analysis of the region upstream of farR revealed an RND efflux pump, farE, the
expression of which is induced by antimicrobial uFFA, including linoleic and arachidonic
acid. Importantly, a single nucleotide polymorphism causing a His121Tyr substitution in
FarR caused increased expression of farE, in the absence of an inducing stimulus, and a
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significantly higher induced level of expression when cells are exposed to linoleic acid.
Moreover, we showed that farE is required to support the growth of S. aureus in the
presence of sub-inhibitory concentrations of linoleic acid, and that resistance to linoleic
acid is proportional to farE expression (1).
The regulation of lipid homeostasis is essential to maintaining bacterial physiology and
here we report the first steps towards understanding how FarR regulates the expression of
farE. We previously established that farE is induced by antimicrobial fatty acids in a
farR-dependent manner, providing evidence that farR does not function strictly as a
repressor. TFRs are mainly repressors in nature, with limited reports of unconventional
TFRs that have dual roles (10–12). SczA of Streptococcus pneumoniae, for instance, is an
unconventional TFR that binds an operator site in the absence of its ligand, zinc, and
binds another distinct operator site further upstream to act as an activator and help recruit
the transcription machinery (13). We here examine FarR-DNA interaction and establish
that FarR binds to distinct operator sites in the intergenic segment between the divergent
farE and farR, and nucleotide mutation in these operator sites abrogated protein binding
of FarR to these sites. Using a gene-reporter system, we determine that FarR, similar to
the majority of TFRs, is auto-regulatory in nature and that the operator site responsible
for auto-repression spans the -10 element of PfarR as well as +1 transcriptional start site of
farR. Finally, we establish that FarR binds to a DNA operator site upstream of the
putative farE promoter that may have a role in farE activation.

3.2% Materials%and%methods%%
3.2.1%

Bacterial%strains%and%growth%conditions%%

A list of bacterial strains used in this study is provided in Table 3.1. Bacterial cultures
were maintained as frozen stocks at -80°C in 20% glycerol and streaked on tryptic soy
agar (TSA) plates (S. aureus) or Luria Bertani (LB) agar plates (E. coli), when needed.
Antibiotics were added when needed at the following concentrations: chloramphenicol, 5
µg/ml; erythromycin, 5µg/mL; anhydrotetracycline, 250 ng/ml; ampicillin, 100 µg/mL
and kanamycin, 50 µg/mL. For growth analyses, single colonies were inoculated into 3
mL TSB or LB broth supplemented with antibiotics, when required, and incubated

114

overnight at 37°C on an orbital shaker (VWR). Cultures were then diluted into 25 mL
TSB to a starting OD600 of 0.01 and incubated at 37°C on an orbital shaker at 180 rpm.
For fatty acids supplementation, 25 mL TSB supplemented with 0.1% DMSO was used.

3.2.2%

Construction%of%S./aureus/USA300ΔfarER/and%
USA300ΔfakA/

In-frame, markerless deletion of both farE and farR as well as fakA was achieved using
pKOR1 as previously described (14). Briefly, 1000 bp segments located upstream and
downstream of the farE-farR locus were amplified using PCR primers that incorporate
attB1 and attB2 sequences as well as a SacII cut site to allow for ligation of the resulting
amplicons. The segment upstream of farE was amplified using farE-UP-attB1 that
incorporates attB1 sequence on the 5#-end of the segment, and farE-UP-SacII that
incorporates a SacII cut site on the 3#-end of the segment. The segment downstream of
farR was amplified using farR-DW-SacII that incorporates a SacII site at the 5#-end of the
segment, and farR-DW-attB2, which incorporates an attB2 sequence on the 3#-end of the
segment. Similarly, the fakA mutant was constructed by amplifying 1000 bp segments
located upstream and downstream of fakA using PCR primers that incorporate attB1 and
attB2 sequences as well as a SacII cut site to allow for ligation of the resulting amplicons.
The amplicons were subsequently purified, digested with SacII and ligated together using
T4 DNA ligase (NEB). The resulting fragment was then introduced into the pKOR1
vector using site-specific recombination. This was achieved using BP Clonase II
(Invitrogen) to facilitate recombination between the attB1 and attB2 sequences on the
ligated PCR product and the attP1 and attP2 sites on the vector, generating pKORΔfarER
or pKORΔfakA. The vectors were constructed in E. coli DH5α background first and
subsequently passaged through S. aureus RN4220 at 30°C before electroporation into S.
aureus USA300. In-frame allelic replacement of farER or fakA was then achieved by a
two-step temperature shift and anti-sense counter-selection as previously described (14).
The USA300ΔfakA-ΔfarER double mutant was constructed by electroporating
pKORΔfarER into S. aureus USA300ΔfakA, followed by in-frame allelic replacement as
described above.
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3.2.3%

Construction%of%complementation%and%reporter%gene%
constructs%

Oligonucleotides used to generate reporter gene constructs, or to complement mutants
can be found in Table 3.2. For complementation, we utilized the pLIfarR and pLIfarE
complementation vectors that we previously made (1). farE was cut out of pLIfarE using
the restriction enzymes KpnI and SacII, and subsequently gel purified for ligation with
pLIfarR in E. coli DH5α background. The presence of ligated genes (farER) was
confirmed by PCR and DNA sequence analysis. The pLIfarER construct was then
passaged through S. aureus RN4220 and electroporated into USA300ΔfarER. The
complementation construct pLIfarR was modified using the mutagenic primers PfarR10G>A-F and PfarR-10G>A-R, using protocols and reagents following the QuikChange
Site-Directed Mutagenesis Kit (Stratagene), to construct pLIfarRTAG>A, harboring a single
nucleotide substitution within the -10 motif of the PfarR promoter. To construct reporter
gene constructs we utilized the pGYlux vector where the luciferase operon can be driven
from our promoter of interest (15). We previously constructed farE::lux by cloning a 397
bp fragment, which included the entire intergenic segment between farE and farR and
additional sequence from the 5#-end of farE and 5#-end of farR, in front of the lux operon
(1). To localize the farR promoter, we cloned two farR segments into the pGYlux vector;
the larger segment (246 bp) that made up pGYfarR::lux1 was amplified using primers
pGYfarR1-F and pGYfarR-R, and the smaller segment (164 bp) that made up
pGYfarR::lux2 was amplified using primers pGYfarR2-F and pGYfarR-R. Both
segments were cloned into the BamHI and SalI sites of pGYlux (15). pLIfarRTAG>A was
used as a template in PCR with primers pGYfarR1-F and pGYfarR-R, and the amplicon
was then cloned in pGYlux to generate pGYfarRTAG>A::lux.
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Table 3.1 Strains and plasmids used in Chapter 3.
Strain or plasmid
Strains:
S. aureus:
USA300LAC

Description

Source

Community-acquired methicillin-resistant S. aureus,
wild-type strain cured of antibiotic resistance plasmids

(16)

RN4220

Restriction endonuclease deficient lab strain of S. aureus
capable of accepting foreign DNA

(17)

USA300ΔfakA

USA300LAC with markerless deletion of fakA
(SAUSA300_1119)

This study

USA300ΔfarER

USA300LAC with markerless deletion of farE
(SAUSA300_2489) and farR (SAUSA300_2490)

This study

USA300ΔfakAΔfarER

USA300LAC with markerless deletion of fakA, farE, and
farR

This study

USA300ΔfarER
(pLI50)
USA300ΔfarER
(pLIfarE)

USA300ΔfarER with empty pLI50 vector, Cmr

This study

USA300ΔfarER complemented with native farE, cloned
in pLI50, Cmr

This study

USA300ΔfarER
(pLIfarR)

USA300ΔfarER complemented with native farR, cloned
in pLI50, Cmr

This study

USA300ΔfarER
(pLIfarR7)

USA300ΔfarER complemented with farR from SNPcontaining clone FAR7, cloned in pLI50, Cmr

This study

USA300ΔfarER
(pLIfarER)

USA300ΔfarER complemented with native farER, cloned
in pLI50, Cmr

This study

λ- φ80dlacZΔM15Δ(lacZYA-argF)U169 recA1 endA1
hsdr17(rK- mK-) supE44 thi-1 gyrA relA1
F-, Φ80ΔlacM15, thi, lac-, mtl-, recA+, KmR

Invitrogen

E. coli-S. aureus shuttle vector
pLI50 with native farE gene
pLI50 with native farR gene
pLI50 with farR gene from the variant FAR7 clone
pLI50 with farR gene harboring a TAG>A mutation in
the -10 element of PfarR

(18)
(1)
(1)
(1)
This study

E. coli:
DH5α
M15[pREP]
Plasmids:
pLI50
pLIfarE
pLIfarR
pLIfarR7
pLIfarRTAG>A
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Qiagen

pKOR1
pKORΔfarER
pKORΔfakA
pGYlux
pGYfarE::lux
pGYfarR::lux1
pGYfarR::lux2
pGYfarRTAG>A::lux
pQE30
pQE6His-farR
pQE6His-farR7
pUC18

E. coli-S. aureus shuttle vector containing Pxyl-tetO and
expressing antisense secY RNA
pKOR-1 containing upstream and downstream flanking
sequences for deletion of farER
pKOR-1 containing upstream and downstream flanking
sequences for deletion of fakA
E. coli-S. aureus shuttle vector harboring promoterless
luxABCDE operon
E. coli-S. aureus shuttle vector containing PfarE for
luxABCDE operon
E. coli-S. aureus shuttle vector containing P1 of farR for
luxABCDE operon
E. coli-S. aureus shuttle vector containing P2 of farR for
luxABCDE operon
E. coli-S. aureus shuttle vector containing mutated P1 of
farR for luxABCDE operon
E. coli vector for IPTG-inducible expression and
incorporation of an N-terminal 6×His tag
pQE30 containing 6×His tagged farR
pQE30 containing 6×His tagged farR from the variant
FAR7 clone
E. coli cloning vector
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(14)
This study
This study
(15)
(1)
This study
This study
This study
Qiagen
This study
This study
(19)

Table 3.2 Oligonucleotides used in Chapter 3.
Oligonucleotide
farR-DW-SacIIa
farR-DW-attB2
farE-UP-attB1
farE-UP-SacIIa
fakA-UP-attB1
fakA-UP-SacIIa
fakA-DW-SacIIa
fakA-DW-attB2
pGYfarE-Fb
pGYfarE-Rc
pGYfarR1-Fb
pGYfarR2-Fb
pGYfarR-Rc
farR-GSP1
farR-GSP2
farR-GSP3
AAP
AUAP
M13-F
M13-R
farR-6H-Fd
farR-6H-Re
OPE-F
OPE-R
OPIN-F
OPIN-R
OPR-F
OPR-R
OP1
OP2
OP3
OP4
OP5
OP5A

Sequence 5# to 3#
ggacctccgcggGGCGAAGATATTGATAACATTTTCC
ggggaccactttgtacaagaaagctgggtGGTAAATTAGAACAAGGTGGCG
ggggacaagtttgtacaaaaaagcaggctTTCCTTTGCCTGTACGTGC
ggacctccgcggAACGATGGCATTGTACCAAG
ggggacaagtttgtacaaaaaagcaggctGCGTGTGAACGTCTGTTACCAGTC
GAAGC
ggacctccgcggCATTTCAAGTTGTCCTCCTAAGCTTTCTTGC
ggacctccgcggGTTCATGAAGGTGGACAACCAATTTATC
ggggaccactttgtacaagaaagctgggtGATGACTTTTCTAATCTATTTAGCC
ATTGC
cccggatccTTGTACGGTGTACGAGTGCG
cccgtcgacCGGTGCATTTGTAGCAAGTG
cccggatccTGCAGCTACAATCACTATCCATGC
cccggatccGCCAAAGTATATTGCCTCC
cccgtcgacTAAATCAGTCTCTTTCATCTACATTTCTCC
TTATCTGGGATGTCGCTG
CCCGTCGACTCAGCGTCTTCTTCTTGG
ATTGTCGACACTCATCGTTTGGAATGG
GGCCACGCGTCGACTAGTACGGG/ideoxyI/ideoxyI/GGG/ideoxyI/i
deoxyI/GGG/ideoxyI/ideoxyI/G
GGCCACGCGTCGACTAGTAC
CGCCAGGGTTTTCCCAGTCACGAC
AGCGGATAACAATTTCACACAGG
CTACACACAAAGGAGAAATGTAgagctcATGAAAGAGACTGAT
TTACGAG
GGTAACGCTCATGAGTTTCTaagcttCTATTTAATCTTAATATTG
ATTAATCTATGG
GTTTTTCAATCTTTTTATTCGTATCTAACG
GATGGGGACATTCATCGC
CCCCATCTTATATAAAAATTTTGCC
CTACATTTCTCCTTTGTGTGTAG
GATGAAAGAGACTGATTTACGAG
CATATTTATCATAAAAATGTTTATAAAATGTTGTACGG
GTTATAGTTTAAATATACAGTGTAGATTATTGTTCGATTATAG
GTATATTGCCTCCTTTTAAAATCAACGTTATAGTTTAAATATA
TTATTGTTCGATTATAGTATCTATCCCCGACCTCTTAAAGAAT
GAATCAATTGGAAAATTTTGTATATTAAACTACACACAAAGG
AGAAATGTAG
AGTTTAAATATACAGTGTAGATTATTGTT
AGTTTAAATATACAACACCAATTATTGTTCG
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OP5TAG>A
OP5ΔTAG
OP6
OP7
OP11
OP12
OP13
OP13A
OP13TAG>A
PfarR-10G>A-F
PfarR-10G>A-R

AGTTTAAATATACAGTGTAAATTATTGTT
AGTTTAAATATACAGTGATTATTGTT
AAATCAACGTTATAGTTTAAATATACAG
TGTAGATTATTGTTCGATTATAGTATCT
GTATATTGCCTCCTTTTAAAATCAACGTTA
GCCTCCTTTTAAAATCAACGTTATAGTTTA
TTTTAAAATCAACGTTATAGTTTAAATATA
TAAAATCCATTGTATAGTTTAAAT
TTTTAAAATCAACGTTATAATTTAAATATA
CCTTTTAAAATCAACGTTATAATTTAAATATACAGTGTAG
CTACACTGTATATTTAAATTATAACGTTGATTTTAAAAGG

Lower case nucleotides are attB2 and attB1 site for cloning into pKOR1 vector. Lower
case and bold nucleotides indicate the addition of 5’ sequences to incorporate restriction
endonuclease cut sites as follows aSacII, bBamHI, cSalI, dSacI, and eHindIII. Nucleotides
in bold show the locations of site-directed mutations.
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3.2.4%

RNA%isolation%and%5#Grapid%amplification%of%complementary%
DNA%ends%

RNA was isolated from S. aureus cells (USA300 and FAR7) grown to mid-exponential
phase (OD600 of 0.5) in TSB supplemented with 20 µM linoleic acid, using Aurum™
total RNA kit (Bio-Rad) as per manufacturer’s instructions. Synthesis of first-strand
cDNA was prepared using 1 µM farR-gene specific primer farR-GSP1, 1.5 µg of RNA,
50 µM dNTPs, and 20 units of SuperScript™ II reverse transcriptase (Invitrogen),
followed by incubation at 42°C for 50 minutes. The original mRNA template was
subsequently removed by treatment with a mixture of RNaseH (0.5 units) and RNase T1
(50 units) at 37°C for 30 minutes. The cDNA was then purified using BioArray® cDNA
purification kit (Enzo Life Sciences) as per manufacturer’s instructions to eliminate
unincorporated farR-GSP1 and dNTPs. A dC-tail was added to the 3#-end of the purified
cDNA using 20 units of terminal transferase (Roche) and 0.5 mM CTP, and the resulting
C-tailed cDNA was utilized in a PCR reaction using abridged anchor primer (AAP) and
nested farR gene specific primer farR-GSP2. A second PCR was then conducted, using
the first PCR product as a template, with abridged universal amplification primer
(AUAP) and a nested farR-GSP3 containing a SalI restriction cut site to allow for cloning
into pUC18. Cloned products were sequenced using M13-F and M13-R primers that
flank the multiple cloning site of pUC18. The +1 transcription start site was identified as
the first nucleotide following the poly C- or G-tail, depending on the orientation of the
cloned insert.

3.2.5%

Construction%and%purification%of%recombinant%FarR%

farR genes from both USA300 and FAR7 were cloned in pQE30 to allow for expression
with an N-terminal 6×His-tag using primers farR-6H-F and farR-6H-R. Recombinant
proteins were expressed and purified from E. coli M15[pREP]. Bacterial cultures were
grown at 37°C in LB (Sigma Aldrich) supplemented with 100 µg/mL ampicillin and 50
µg/mL kanamycin, to an OD600 of 0.8 before the addition of 0.1 mM of isopropyl 1-thioβ-D-galactopyranoside (IPTG) and incubation at room temperature with shaking for
additional 18 hours. Cells were harvested by centrifugation and resuspended in binding
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buffer (20 mM sodium phosphate, 0.5 M NaCl, 40 mM imidazole, pH 7.4), lysed in a cell
disruptor (Constans System Ltd.) at 25000 psi, and subsequently pelleted at 3000 rpm for
15 minutes. Supernatant was then ultracentrifuged for 50 minutes at 50,000 xg in a
Beckman Coulter Optima L-900K ultracentrifuge, after which the soluble fraction was
filtered through a 0.45µm Acrodisk® syringe filter (Pall Laboratory). The lysate was
applied onto a 1 mL His-Trap nickel affinity column (GE Healthcare) that was
equilibrated with binding buffer. After washing extensively with binding buffer, bound
His-tagged protein was eluted over a linear imidazole gradient up to 0.5 M imidazole in
20 mM sodium phosphate. Column fractions were assessed by SDS-polyacrylamide gel
electrophoresis to check for purity, and fractions were then pooled and dialyzed in 20
mM sodium phosphate, 0.5 M NaCl, pH 7.4 at 4°C overnight (Appendix 8). Protein
concentration was determined by Bradford assay using Bio-Rad protein assay reagent.

3.2.6%

FarRGDNA%interaction%studies%%

Electrophoretic mobility shift assays (EMSA) were performed using recombinant 6×Histagged FarR and fluorescently-labeled duplex oligonucleotides probes. A list of
oligonucleotides used in this study is provided in Table 3.2. IRDye-labeled singlestranded oligonucleotides were purchased from Integrated DNA technologies (IDT®)
and complementary oligonucleotides were annealed at 100 µM each in 10 mM Tris, pH
8.0, 0.1 mM EDTA, by incubation at 95°C for 5 minutes followed by cooling down
slowly to room temperature for 45 minutes. Each 25 µL EMSA reaction contained 5
pmol of fluorescently-labeled probe, up to 2 µM purified FarR, 240 µg/mL bovine serum
albumin (BSA) and 15.2 µg/mL poly[d(I-C)] in 10% glycerol, 15 mM Tris-HCl pH 8.0,
0.5 mM MnCl2, 60 mM KCl, 0.5 mM MgCl2, and 8 mM dithiothreitol (DTT). Reaction
mixtures were incubated at room temperature for 60 minutes, after which they were run
on a 6% TBE-acrylamide gel for 45 minutes at 120V, and imaged using an Odyssey
imager (LI-COR Biosciences). FarR-DNA interaction was determined as the conversion
of unbound DNA probe to slow-moving protein-DNA complex. In competition assays,
unlabelled competitor probes harboring specific nucleotide substitutions were added in
50-fold excess compared to that of the labelled probes.

122

3.2.7%

Antibody%production%and%western%blotting%

Rabbit polyclonal antisera recognizing FarR were generated by ProSci Incorporated
(Poway, CA, USA). Two hundred µg of recombinant 6×His-FarR emulsified in complete
Freund’s Adjuvant was used for the initial injection of rabbits, and 100 µg of the
recombinant protein emulsified in incomplete Freund’s Adjuvant was subsequently used
for each booster immunization. Rabbits were immunized every other week for a total of
six weeks. For western blotting, cell lysates of E. coli complemented with pLI50
harboring native farR and farR bearing mutated PfarR were prepared by incubating washed
cells with lysis buffer (150 mM NaCl, 5 mM EDTA pH 8.0, 50 mM Tris-HCl pH 8.0, 1%
(v/v) Triton X-100, 0.5% (v/v) SDS), supplemented with EDTA-free protease inhibitor
cocktail (Roche), at room temperature for two hours with agitation, followed by
centrifugation at 4,200 x g for 20 minutes. After determining protein content of the
clarified cell lysate, samples containing 25 µg of total cell lysate protein were subjected
to SDS-PAGE using a 12% polyacrylamide resolving gel. Proteins were then transferred
to PVDF membrane following standard protocols. Primary anti-FarR antiserum was used
at a dilution of 1:5000 followed by secondary IRDye800-conjugated goat anti-rabbit IgG
(Jackson Immunoresearch Laboratories Inc.). Membranes were imaged using Odyssey
imager (LI-COR Biosciences).

3.2.8%

Murine%infection%model%

We utilized a skin abscess infection model as described by Malachowa et al. with
adaptation (20). Briefly, female BALB/c mice were anesthetized by an isoflurane
vaporizer, and flanks were treated with Nair hair removal lotion first, then shaved by a
battery-operated trimmer one day prior to the inoculation to allow for proper visualization
and measurement of abscesses. On infection day, bacterial cultures were inoculated at an
OD600 of 0.01 from an overnight stationary phase culture, and grown at 37°C with
shaking to an OD of 2.0. Bacteria were harvested by centrifugation, washed twice with
sterile PBS, and resuspended in sterile PBS to obtain a final concentration of 2x108
cfu/mL. Bacterial suspensions were kept on ice until injection. Colony forming units in
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each suspension were confirmed by plating on TSA and enumerating the next day. Mice
were anesthetized by an isoflurane vaporizer, weighed, then challenged by subcutaneous
injection of 50 µl of bacterial suspension (1x107 cfu), or PBS only. Abscess progression
was pictured daily to quantify abscess area by Image J. Animal weight was also
monitored daily for three days, after which the animals were sacrificed, and the lesions
were imaged. The infected lesions were then excised, homogenized in PBS-0.01% Triton
X-100, and plated on Mannitol Salt Agar (MSA) for enumeration.

3.2.9%

Computer%analyses%

Protein structural modeling was done using PHYRE2 (21). Analysis of DNA sequences
and primer design were done using MacVector (Version 14.0.4 MacVector Inc.).
Promoter predictions were performed using the Berkeley Drosophila Genome Project
(http://www.fruitfly.org/seq_tools/promoter.html), with adjustments for detection of
prokaryotic promoters. Multiple sequence alignment was done using ClustalW 1.4 (22).
Data points for growth, viability, and luciferase reporter gene assays were plotted and
analyzed using GraphPad Prism, version 7.0. Statistical significance was determined
using unpaired one-tailed Student’s t-test and two-way ANOVA using the statistical
feature of GraphPad Prism, version 7.0.

3.3% Results%%
3.3.1%

Deletion%of%farER%results%in%loss%of%inducible%resistance%to%
linoleic%acid%

In our previous work, transposon insertions in farE and farR were used to demonstrate
that the farE efflux pump, and the divergent transcriptional regulator farR were both
required for inducible resistance of USA300 to the bactericidal activity of 100 µM
linoleic acid (1) . To confirm these observations, and to enable more detailed studies on
gene expression and structure-function relationships USA300ΔfarER, where both genes
are deleted, was constructed using pKOR1 markerless mutagenesis. In agreement with
our previous observations, USA300ΔfarER suffered a loss of resistance to the
bactericidal activity of 100 µM linoleic acid (Fig. 3.1A).
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3.3.2%

farR%is%required%for%farE%induction%%%%

The conventional mechanism of action of TFRs is to repress the expression of divergent
genes. In previous work, we have shown that when assaying farE::lux reporter gene
construct in USA300, the reporter activity was negligible in TSB only, but induced in
TSB supplemented with 20 µM linoleic acid. We also observed that the reporter activity
was negligible in USA300farR::ΦNE background suggesting that farR is required for
induction of farE expression. Additionally, USA300ΔfarER was unable to grow in TSB
supplemented with 50 µM linoleic acid, and complementing with farE alone did not
rescue growth, whereas complementing with pLIfarER restored growth over 8 hours of
incubation (Fig. 3.1B). As expected, when assaying farE::lux activity in USA300ΔfarER,
there was negligible induction of farE in the absence of farR function (Fig. 3.2). These
data confirm that functional farR is indeed required for expression of farE.
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Figure 3.1 farER contributes to resistance of S. aureus USA300 to linoleic acid. A.
Bactericidal assay: USA300, USA300ΔfarER, or USA300ΔfarER + pLIfarER were
grown to mid-exponential phase in TSB + 20 µM linoleic acid, and then diluted to 106
cfu/mL in fresh TSB containing 100 µM linoleic acid. Viable cell counts were taken at
hourly intervals. B. Growth assay: USA300ΔfarER complemented with pLIfarE,
pLIfarER, or pLI50 vehicle was inoculated into TSB + 50 µM linoleic acid, and growth
(OD600) was monitored at hourly intervals. Each data point represents mean value of
quadruplicate cultures. Error bars represent Standard Error of the Mean.
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Figure 3.2 farR is required for farE induction. Growth (OD600; open symbols) and
relative luminescence units (RLU/OD; closed symbols) of USA300 and USA300ΔfarER
harboring the pGYfarE::lux reporter construct are shown. Strains were grown in TSB or
TSB supplemented with 20 µM linoleic acid (LA). Each value represents the mean and
standard deviation of three separate cultures, and each culture was subjected to
quadruplicate luminescence readings at each time point. Error bars represent Standard
Error of the Mean.
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3.3.3%

Identification%of%farR%promoter%and%transcription%start%site%%

The neighboring genes farE and farR are divergently transcribed. The intergenic segment
between farE and farR translational start sites is 145 nucleotides, and bioinformatics
analyses identified two potential farR promoters, P1 and P2, in this intergenic segment.
P1 overlaps with the farE translational initiation codon on the minus strand, and is
located 145 bp upstream of the translational initiation codon of farR, whereas P2 is
located 132 bp upstream of the translational initiation of farR (Fig. 3.3A). To confirm
PfarR in the context of transcriptional initiation of farR, we used 5#-RACE to determine
the +1 site of farR. The transcription start site of farR was located at 104 bp from the
translation start site in two out of three independent experiments, and one experiment
showed that the transcription start site was 105 bp from the gene’s start codon. These
results correspond to P2 being the primary PfarR (Fig. 3.3A).

To confirm this, we

designed two overlapping PfarR segments to clone reporter gene fusions in pGYlux. The
larger construct, farR::lux1, harbors structural elements of both promoters P1 and P2
whereas the shorter truncated construct, farR::lux2, lacks the -35 element of P1. When
these reporter constructs were assayed in E. coli, both displayed luminescence activity
but the truncated farR::lux2 exhibited 8-fold less activity compared to that of the larger
farR::lux1 construct (Fig. 3.3B). These data suggest that P2 is sufficient to promote
transcription of the gene, although contribution of the overlapping P1 cannot be excluded.
In a similar fashion, bioinformatics analyses identified a putative farE promoter in the
farER intergenic segment that is located 102 bp upstream of the translational initiation
codon of farE; however, 5#-RACE experiments failed to determine the +1 transcription
start site of farE.

3.3.4%

Expression%of%farR%is%subject%to%autoGregulation%

Members of the TetR family of transcriptional regulators are typically subject to autoregulation, including CamR in Pseudomonas putida, TcmR in Streptomyces glaucescens
and the well-characterized TetR. Conversely, QacR of S. aureus was not subject to autoregulation (23). To determine whether farR is auto-regulated, we assayed farR::lux1
activity in both USA300 and USA300ΔfarER backgrounds, and observed that the
reporter activity was negligible in USA300, but was strongly de-repressed in
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USA300ΔfarER. These data support farR auto-regulation such that farR::lux reporter
activity is higher in the USA300ΔfarER background, due to the absence of functional
FarR, concomitant with de-repression of PfarR. (Fig. 3.3C).
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Figure 3.3 Nucleotide sequence of farER intergenic segment showing PfarR and PfarE
promoter features (A), and farR::lux reporter gene assays conducted in E. coli (B)
and S. aureus (C). The farER intergenic segment contains two potential PfarR promoters,
P1 and P2, and a predicted PfarE promoter. The experimentally determined +1
transcription start site (TSS) of P2farR was confirmed using three independent 5!- RACE
experiments. Translation initiation sites of farE (TTG) and farR (ATG) are in gray boxes.
RBS (ribosomal binding site) of farE and farR are shown.

B. Assay of farR::lux

promoter constructs in E. coli. The larger farR::lux1 construct contains both P1 and P2
promoters, while in farR::lux2, the P1 promoter is truncated within the predicted -35
promoter element. C. Assay of farR::lux1 in S. aureus USA300 and USA300ΔfarER.
Each value represents the mean and standard deviation of three cultures, and each culture
underwent quadruplicate luminescence readings at OD600 of approximately 0.1 (B), and
0.5 (C). Results are shown normalized to the optical density. Statistical significance is
determined using unpaired one-tailed Student’s t-test, where *P <0.05 and ****P <
0.0001. Error bars represent Standard Error of the Mean.!
!
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3.3.5$

Identification$of$FarR$operator$sites$

Although the divergent arrangement of the farE-farR genes matches the classical
paradigm of TFR function, in which the TFR serves to repress the divergently transcribed
gene, our data indicate that FarR is needed to express FarE, rather than functioning as a
repressor. However, as with a number of other TFR’s, our data indicate that FarR
represses its own expression. Therefore, we hypothesized that the farER intergenic
segment should have two distinct operator sites to support binding of FarR; one to
facilitate auto-repression of PfarR, and the other to function as an activator of PfarE. To
identify potential operator sites, recombinant N-terminal 6×His-tagged FarR was
expressed in E. coli and purified by metal affinity chromatography, for use in
electrophoretic mobility shift assay (EMSA) experiments.
To determine if binding determinants are localized within the 145 bp farER intergenic
segment, PCR with IRDye800 labelled primers was first employed to generate three ~
160 bp probes that collectively encompass the entire intergenic segment, the 5´-end of
farR, and the 5´-end of farE (OPIN, OPR, and OPE, respectively). Using EMSAs, 6×HisFarR bound only to probe OPIN spanning the intergenic segment between the two genes,
causing a mobility shift. This binding exhibited two protein-DNA complexes indicating
that there are multiple binding sites of FarR within the intergenic segment (Fig. 3.4B).
Since this confirmed that the primary FarR binding sites are contained entirely within the
intergenic segment OPIN, we proceeded to identify potential operator sites within this
segment. TFRs bind palindromic, and often repeated, DNA operator sequences. Based on
Pustell DNA matrix analysis of the 145 nucleotide intergenic segment that separates the
translational starts of farE and farR, we identified a 17 nucleotide pseudo-palindrome
containing three mismatches (PAL1), flanked by imperfect 16 nucleotide direct repeats
(IR1 and IR2). These features span the transcriptional start site of the putative farE
promoter region on the minus strand, and that of farR on the plus strand, thus comprising
a likely site for binding of the FarR regulatory protein (Fig. 3.4A).
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To evaluate the ability of these features to support FarR binding, we conducted EMSAs
with 43mer probes centered on the intergenic segment; FarR bound to probe OP1 that
encompasses the pseudo-palindrome as well as IR1 and IR2. FarR also bound OP2,
which encompasses 6 nucleotides of 5!-end of the pseudo-palindrome, IR1 and structural
elements of PfarR as well as the +1 transcription start site of farR, but failed to bind to OP3
that contains 2 nucleotides of the 3!-end of the pseudo-palindrome, IR2 and structural
elements of the putative PfarE as well as the +1 transcription start site of farE.
Additionally, the 52mer probe OP4, that spans the -35 element and additional sequence
upstream of the putative PfarE, also supported FarR binding (Fig. 3.4C). Interestingly, we
identified a second pseudo-palindrome (PAL2) that bears similarity to PAL1 and is
located in OP4 (Fig. 3.4A). PAL2 is a 16 nucleotide palindrome with four mismatches
located 12 bp upstream of the -35 element of PfarE. Therefore, there appears to be a FarR
binding site centered on the structural elements of PfarR, as well as another binding site
upstream of the putative PfarE.
To further refine these binding sites, we designed 28mer probes centered on OP1and OP2
(Fig. 3.4A). The probe OP5 is centered over the pseudo-palindrome, as well as 11
nucleotides of the 3!-end of IR1 and 8 nucleotides of the 5!-end of IR2. OP6 contains 9
nucleotides of the 5!-end of the pseudo-palindrome and IR1, whereas OP7 contains 8
nucleotides of the 3!-end of the pseudo-palindrome and IR2. FarR bound to OP5 and
OP6, both of which span the +1 transcriptional start of farR, but did not exhibit any
binding to OP7 (Fig. 3.4D).
The OP5 probe contains the entire PAL1, and to confirm specificity of protein-DNA
interaction at this location, we employed competition EMSAs. In these assays, 50-fold
excess of unlabeled competitor DNA is added to the reaction mix prior to incubation with
the labeled probe. Specificity is confirmed by loss of binding to the labelled probe and
thus lack of mobility shift. To this end, we designed a probe, OP5A, where the central
GTGTAG sequence of the pseudo-palindrome was mutated to ACACCA and used it in a
competition EMSA with the labelled OP5. Altering this central sequence of OP5
abolished the competition for FarR binding completely, confirming specificity of FarR
binding to this operator site (Fig. 3.4E).
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Figure 3.4 FarR operator sites are located in the farER intergenic segment. A. 145nucleotide intergenic segment separates the translational initiation of farE and farR.
Pseudo-palindromes PAL1 and PAL2 are in gray boxes. Inverted repeats IR1 and IR2 are
underlined. Core promoter elements are indicated. Transcription start sites are in bold.
For initial EMSA experiments with 6×His-FarR, PCR was employed to generate 167 bp
IRDye-labelled probes OPIN, OPR, and OPE that span the entire intergenic segment, the
5"-end of farR, and 5"-end of farE, respectively. The overlapping 43mers OP1, OP2, and
OP3, and the 52mer OP4 collectively span the entire intergenic segment. The 28mers
OP5, OP6 and OP7 and the 30mers OP11, OP12 and OP13 were designed to further
narrow down the operator site that supports FarR binding. B. FarR binds operator OPIN
spanning the farER intergenic segment. In each reaction, 5 pmol of operator DNA is
incubated with 0, 0.5 and 2 µM protein. C. and D. FarR binds to OP1, OP2, OP4, OP5
and OP6 and failed to bind OP3 and OP7. Each reaction contained 5 pmol of DNA with
or without 2 µM protein. E. FarR binds to OP5 which spans the +1 transcription start site
of farR, and nucleotide substitutions in PAL1 of this probe abrogates FarR binding.
Competition EMSA experiments were done by incubating FarR with excess (50X) of
unlabelled competitor probe for 30 minutes prior to incubating with 5 pmol of labelled
probe.!
!
!
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3.3.6$

FarR$binds$OPAct$and$OPRep$

We have strong evidence that farR is required for farE induction (Fig. 3.2).
Consequently, it appears that FarR does not function strictly as a transcriptional
repressor, as is the case with most TFRs. There have been reports of two TFRs, LuxR in
Vibrio harveyi and SczA in Streptococcus pneumoniae, that deviate from the norm of this
family, where the protein functions as both repressor and activator depending on the
presence or absence of a modulating ligand (13, 24, 25). This lead us to reason that FarR
functions in a similar fashion where it binds a certain operator to function as a repressor
and binds another operator site where it functions as an activator. Since we have evidence
that FarR bound the operator OP4 located upstream of the putative PfarE, and that no other
sequences upstream of PfarE even within the 5"-end of farR supported protein binding,
we speculated that binding to this operator would be most likely to activate farE.
Additionally, FarR is subject to auto-regulation, and since operator probes OP2, OP5 and
OP6 all support FarR binding, span PfarR and immediately downstream of PfarE, we
reasoned that binding to one of these operators would be to repress farR, and perhaps
farE. To elucidate the minimal operator site that supports FarR binding for repression, we
designed 30mer probes that span the structural features of PfarR, which is contained within
the larger OP2 probe. OP11 spans 30 bp from the 5"-end of OP2, including the -35
element of PfarR. OP12 spans the center of OP2 and PfarR including 4 bp of the -35
element and the entire -10 sequence of the promoter. OP13 contains 30 bp from the 3"end of OP2, the -10 sequence of PfarR as well as the transcriptional start site of farR (Fig.
3.4A). We performed competition EMSAs where 50-fold excess of these unlabelled
competitor DNA probes are added prior to incubation with the labelled probe OP2. Both
OP11 and OP12 were unable to compete with OP2, whereas OP13 competed effectively,
and prevented protein binding to the labelled OP2, such that no mobility shift was
observed (Fig. 3.5).
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Figure 3.5 Competition EMSA with OP2 reveals that an operator site for binding of
FarR is located within OP13. EMSA reactions contained 0, 0.5, or 2 µM 6×His-FarR,
250 pmol of unlabelled competitor, and 5 pmol of labelled OP2 probe. OP13 competes
successfully with OP2 for binding of FarR, whereas OP11 and OP12 do not.
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From these experiments, there appears to be two distinct operator sites for FarR binding
in the intergenic segment between farE and farR. One operator is OP4, which contains
sequences located immediately upstream of the putative PfarE. Since we established that
farR does not function strictly as a repressor, we reasoned that this operator, hereafter
termed OPAct, is the site of FarR binding to enable activation of farE. Another distinct
operator site spans the overlapping OP5 and OP13 probes. OP5 is centered over the
PAL1 feature, which contains the +1 TSS of PfarR at its 5'-end, while its 3'-end is adjacent
to the +1 TSS of PfarE on the minus strand. OP13 is centered on PfarR, and contains both
the -10 promoter element and +1 TSS of PfarR. Since these two overlapping operator
sequences span PfarR and transcriptional start site of farR, and immediately adjacent to
that of farE, we reasoned that they represent repression operator site, OPRep (Fig. 3.6A).

3.3.7$

OPRep$contains$the$site$of$farR$auto:repression$and$a$
His121Tyr$substitution$in$FarR$causes$relief$of$auto:
repression$$

Since farR is auto-regulatory, we reasoned that one of overlapping operators making up
OPRep is the site of FarR binding to enable auto-repression. In previous work, we
described a fatty acid resistant clone FAR7, which harbored a single nucleotide
polymorphism causing a His121Tyr substitution in FarR. This clone exhibited increased
constitutive levels of farE, even in the absence of fatty acid inducer, and displayed
increased resistance to bactericidal concentrations of linoleic acid (1). When the reporter
gene construct, farR::lux, was assayed in a FAR7 background we noticed a relief of the
auto-repression when compared to wildtype USA300 (Fig. 3.6B). Therefore, it seems that
the His121Tyr substitution, although not located within the N-terminal DNA binding
domain of FarR, still results in less effective auto-repression. As such, we examined the
ability of recombinant 6×His-tagged FarR protein of the variant FAR7 clone, hereafter
termed FarR7, in mobility shift assays parallel to those done with the wildtype FarR
protein. Interestingly, FarR7 was unable to bind to OP2, to which native FarR was able
to bind efficiently (Fig. 3.6C).

OP2 spans PfarR and the +1 transcriptional start site of

farR. To further define the operator sequence that supports differential binding of FarR
and FarR7, we examined FarR7 binding to OP11, OP12 and OP13 that span the entire
length of OP2. Strikingly, FarR7 did not exhibit any binding to OP13, and since FAR7
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displayed a relief of auto-repression, these data suggest that OP13, which spans the -10
promoter element and +1 transcription start site of farR, also represents a site where FarR
binds to mediate auto-repression (Fig. 3.6C).
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Figure 3.6 FarR and the variant FarR7 differ in binding to OP2 and OP13, both of
which span core promoter elements of PfarR. A. Mapping the oligonucleotide probes
relative to core promoter elements of PfarR and PfarE. Overlapping OP5 and OP13 that
support FarR binding are grouped as OPRep. FarR also binds OP4 located upstream of
PfarE, representing a potential activation site, OPAct. B. farR::lux is de-repressed in the S.
aureus FAR7 background. USA300 and FAR7 harboring the farR::lux1 reporter
construct were grown in TSB, and samples were withdrawn at OD600 of approximately
0.5 for the determination of luciferase activity. Each data point represents the mean and
standard deviation of three cultures, and each culture sample was subjected to
quadruplicate luminescence readings at OD600. Statistical significance is determined
using unpaired one-tailed Student’s t-test, where **P <0.01. Error bars represent
Standard Error of the Mean. C. Mobility shift assay showing that FarR7 does not exhibit
any binding to OP2 or OP13. In each reaction, 5 pmol of operator DNA is incubated
with up to 2 µM protein.
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3.3.8$

$Specificity$determinants$of$FarR$binding$

Aside from the sequence similarities between PAL1 and PAL2, the OP4, OP5 and OP13
probes that comprise OPRep and OPAct appear to share no obvious sequence similarities.
However, EMSA experiments confirmed that OP4, OP5 and OP13 can cross-compete for
FarR binding and that nucleotide substitutions in any of them abrogated this competition
completely. Interestingly, all three operators contained a TAG sequence central to each
operator (Fig. 3.7A). To determine if this represents a specificity determinant for protein
binding, we performed a competition EMSA with probes containing nucleotide
substitutions (OP5TAG>A, OP13TAG>A) or deletion (OP5ΔTAG) in this sequence and
found that these mutations eliminated FarR binding (Fig. 3.7B). Furthermore, analysis of
multiple sequence alignment of 13 staphylococcal species that contain divergent farER
revealed that FarR specificity determinants are conserved among these staphylococci.
Importantly, the TAG nucleotides located in OP4, OP5, and OP13 are highly conversed
among these species (Fig. 3.8).
Interestingly, in OP13, the TAG nucleotides are overlapping with the -10 element of PfarR
and this operator is the only operator that exhibited differential binding of FarR and
FarR7. Additionally, our reporter gene assays revealed that farR::lux is de-repressed in
the FAR7 background, thus providing further evidence that OP13 is the site of FarR autoregulation. To correlate these data with in vitro analyses, we introduced the same
substitution in OP13 (OP13TAG>A where the -10 element of PfarR is mutated) into the
existing reporter gene construct, farR::lux by site-directed mutagenesis. When we
assayed the mutated farRTAG>A::lux luciferase activity in USA300, there was a relief of
auto-repression similar to that seen in the USA300ΔfarER and FAR7 backgrounds,
confirming that OP13 is indeed the site of auto-repression of farR (Fig. 3.9A and B). We
also prepared cell lysate fractions from E. coli complemented with pLI50 harboring
native farR and farR bearing mutated PfarR grown in LB and showed by western blotting
that mutating PfarR indeed relieves auto-repression, and promotes FarR expression (Fig.
3.9C).
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Figure 3.7 OP4, OP5 and OP13 cross-compete with each other and nucleotide
substitutions obliterate this competition. A. Sequence similarities shared between OP4,
OP5 and OP13. Arrows indicate the orientation of the similar sequence. The +1 TSS of
farR is labelled +1 in OP5 and OP13, and nucleotides comprising the -10 promoter
element of PfarR are italicized in OP13. B. OP4, OP5 and OP13 cross-compete with each
other. Nucleotide substitutions in OP5 and OP13 (TAG>A) prevented this competition
with OP4, confirming that this site is a specificity determinant for FarR binding. Each
reaction contained 0, 0.5, and 2 µM FarR mixed with 250 pmol of unlabelled competitor
and 5 pmol of labelled probe.
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1 CAAAGTATATT-GCCTCCTTTTAAAATCAACGTTATAGTTTAAATATACAGTGTAGATTATTG----------------TTCGA-TTATAGTA----TCTATCCCCGACCTCTTAAAGAATCAATTGGAAAATTTTGTATATT-AAACTACACACAAAGG 137
1
CAAACTATT-GCCTCCTAATTTAATCAACGTTATAGTTTATACATATAGTGTAGATTATTT---------------ATATTA-ACATTTTACAA-GCTAAGTCGTATTATAAAAAGAACTAATTATGCCAATATGTCTATTTAAACTACAAAAA-GGG 139
1
CAAACTATT-GCCTCCTAAATTAATCAACGTTATAGTTTAAATATATACTGTAGATTATTT---------------CTATCC-ACATATTA-AATGCTTTACCCTTTTATTAAAAGAATTAATTATTACAATTTGTATATTTAAACTACAAATA-AGG 139
1
CAAAGTATT-GCCTCCTTTTAAAATCAACGTTATAGTTTAACTATACAGTGTAGATTATTG----------------TTAGA-TTATATTA----TCTATACCCTACCTCTTAAAGAATTAAATTTTAAAATTTGTATACT-AAACTACACATTAAGG 135
1
CAATCTATT-GCCTCCTCAGATAATCAACGTTATAGTTTAATTGTATAGTGTAGATTATTT---------------ATATTA-ACACAATA-AACGCTGTGTACAATTAATAAAAGAATTAAAAACTGTAATATGCCTATTTAAACTACAGATT-AGG 139
1
CAAAGTATT-GCCTCCTCCTAAAATATACAGTATAGTTTA-TTCTACATAGTAGATTAATTAC-------------GTATCACATATGCTA-CATGGTTAATTATTACCTGTACAGATATATTTCAAGCCTAATATAAGGCTAAACTACACTAA-GGA 141
1
CAAACTATT-GCCTCCTTAATTAATCAACGTTATAGTTTATACATATACTGTAGATTATTT---------------CTATTG-ACATCTTATAATGATTTACCCTATTTAAAAAAGAACTAAATATCCAATTCCGTATATTTAAACTACAGATT-AGG 140
1
CAAACTATT-GCCTCCTTATTTAATCAACGTTATAGTTTAAATGTAATGTGTAGATTATCT---------------ATAATA-TCATAATAACCATGCTCCCCCTAATATATAAAGAATTAAATATACTAAAATGTATATTTAAACTACAAATA-AGG 140
1 CAAATATATT-GCCTCCCTTTAAAATCAACGTTATAGTTTAACTATACAGTGTAGATTATTG----------------TTCGA-TTATAGTA----TCTATACCCTACCTCTTAAAGAATTAAATTTTAAAATTTGTATACT-AAACTACACATTAAGG 136
1
CAAAGTATT-GCCTCCTCTTGATTTCAACGCTATAGTTTAACTGTATAGTGTAGATTATTG----------------TGTGA-TTATAATA----TCTCTACCCTCTTTTTAAAAGAAATAAATAATCGATTGTGTATTTT-AAACTACATATTA-GG 134
1
CAAACTATTTGCCTCCCTATTTAATCAACGTTATATTTTAAATATATTATGTAGATTATCTGTATCTTACATATTCATAGTA-ACATACTAATCAT-TTTTGATTCTTTTATAAAGAATTAATAATATAGAACTGTATATTTAAACTACACATA-AGG 155
1
CAAGCTATT-GCCTCCTTATTTAATCAACGTTATAGTCTAAATATATAGTGTAGATTATTT---------------ACAGTA-CTATACTACTAGTAATTCCCCCAATTT-TAAAGAAATAATAATTATTATATGTATATTTAAACTACAAAAACAGG 140
1
CAAAGTATT-GCCCCCTTCTAAAATCAACGTTATAGTTTAACTATACATTGTAGATTATTTAA------------CATGCCA-ATATGTTA-CATTCTTTTGCTCTGTATTTAAAGTCATAATTAATGATATATGTATAGATAAACTACGGTTTGGAG 143
*
**** ***
** **
**
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Figure 3.8 Multiple sequence alignment of the intergenic segment between farE and farR among S. aureus USA300 and 12
other staphylococcal species that contain divergent farER. The alignment was generated using ClustalW 1.4. Underlined sequences
represent FarR binding motifs in OP13; OP5; and OP4, respectively. Bold and highlighted nucleotides indicate FarR favored
nucleotides at positions 4,5 and 6 of each binding motif.
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Figure 3.9 Nucleotide substitution in the -10 element of PfarR causes a relief of autorepression. A. Growth (OD600; open symbols) and relative luminescence units
(RLU/OD;

closed

symbols)

of

USA300

harbouring

the

pGYfarR::lux

and

pGYfarRTAG>A::lux reporter construct are shown. B. Assay of farR:lux and
farRTAG>A::lux in different genetic backgrounds. S. aureus USA300 harboring either
pGYfarR::lux, or pGYfarRTAG>A::lux were grown in TSB to an OD600 of approximately
0.5, and cultures were processed for determination of luciferase activity. For comparative
purposes, assays were also conducted on cultures of S. aureus FAR7, and
USA300ΔfarER harboring native pGYfarR::lux. Each value represents the mean and
standard deviation of three cultures and each culture underwent quadruplicate
luminescence readings at each time point (A) or at OD600 of approximately 0.5 (B). Error
bars represent Standard Error of the Mean. C. Western blot for detection of FarR protein
in cell lysates of E. coli complemented with pLI50, pLIfarR or pLIfarRTAG>A. Each lane
contains 25 µg of total cell lysate protein, and the control lane contains 5 ng of
recombinant 6×His-FarR.
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3.3.9$

farER$and$fatty$acid$detoxification$

Since S. aureus is incapable of β-oxidation of fatty acids, the metabolic fate of exogenous
unsaturated fatty acids is incorporation into the phospholipid component of the
membrane (26). Parson et al. identified the fatty acid kinase system that is responsible for
processing the exogenous fatty acids that enter the cell. FakB1 and FakB2 bind saturated
and unsaturated fatty acids, respectively. FakA then phosphorylates the fatty acids and
the resulting acyl-PO4 is either extended by FASII machinery or directly incorporated
into phospholipid (27). Importantly, TFRs are typically responsive to small hydrophobic
ligands and crystallography studies of these regulators, including the fatty acid
degradation regulator FadR of Bacillus subtilis, have revealed that endogenous fatty acid
derivatives such as acyl-coAs are often co-crystallized with the protein from the E. coli
host (28). We reasoned that phosphorylated fatty acids could represent the physiologic
ligand that modulates FarR function and interaction with its operator sites. Therefore, we
assayed the reporter gene construct, farE::lux in USA300ΔfakA, to examine farE
expression when the ability to phosphorylate fatty acids is abrogated. Interestingly,
USA300ΔfakA exhibited increased constitutive levels of farE, but expression could not
be further induced by exogenous linoleic acid (Fig. 3.10). Further, this mutant was also
significantly more resistant to killing by bactericidal concentrations of linoleic acid
compared to wildtype USA300, and this phenotype is farE-dependent (Fig. 3.11).
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Figure 3.10 farE::lux exhibits elevated constitutive levels of expression in the
absence of fatty acid kinase, fakA. Growth (OD600; open symbols) and relative
luminescence units (RLU/OD; closed symbols) of USA300 and USA300ΔfakA
harbouring the pGYfarE::lux reporter construct are shown. Strains were grown in TSB or
TSB supplemented with 20 µM linoleic acid (LA). Each value represents the mean and
standard deviation of three separate cultures, and each culture was subjected to
quadruplicate luminescence readings at each time point. Error bars represent Standard
Error of the Mean.
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Figure 3.11 USA300ΔfakA exhibits enhanced resistance to linoleic acid, in a farEdependent manner. A. Strains were grown in 50 µM linoleic acid. B. Strains were
grown to mid-exponential phase in 20 µM linoleic acid, and then diluted to 106 cfu/mL in
fresh TSB containing 100 µM linoleic acid. Viable cell counts were taken at hourly
intervals. Each data point represents mean value of triplicate (A) or quadruplicate (B)
cultures. Error bars represent Standard Error of the Mean.
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5

3.3.10$ farER$influence$virulence$in$a$subcutaneous$abscess$
infection$model&
Studies on staphylococcal murine abscesses reveal that antibacterial activity dwells in the
free fatty acid fraction of the abscesses (29). NorD, a S. aureus multidrug efflux pump
from the major facilitator superfamily, was upregulated during infection and played a part
in the bacterial fitness in an infection abscess model (30). Similarly, NorB in the S.
aureus MW2 strain bestows fitness advantages in the murine subcutaneous abscess
model. The pattern of expression of nor and tet38 pumps in murine abscess models was
found to be distinct from that observed during in vitro cell culture, and this was reasoned
to be due to environmental triggers that dictate the cellular response (31). The fatty acid
kinase, fakA, has also been linked to virulence in a murine model of S. aureus
dermonecrosis; fakA-deficient mutants were more pathogenic than wildtype and formed
larger abscesses (32). To assess the contribution of farER-mediated fatty acid resistance
to virulence in vivo, and link it to the hyper-virulent phenotype observed in a fakAdeficient mutant, we constructed a USA300ΔfakA-ΔfarER double mutant and utilized it
in a murine abscess infection model. In agreement with a previous report, USA300ΔfakA
exhibited a trend towards increased surface abscess area compared to wild type USA300,
but this enhanced virulence phenotype was abrogated in USA300ΔfakA-ΔfarER (Fig.
3.12). In contrast, the single mutant, USA300ΔfarER, showed no difference in virulence
compared to that of wildtype USA300 (Appendix 7). Therefore, the increased basal level
of farE expression in USA300ΔfakA appears to promote increased resistance to
antimicrobial fatty acids in vitro, and enhanced virulence in a subcutaneous abscess
infection model.
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Figure 3.12 USA300ΔfakA-farER exhibits reduced virulence in a murine skin
abscess model of infection. 6-week female BALB/c mice were infected with 2x107 CFU
of USA300, USA300ΔfarER, USA300ΔfakA and USA300ΔfakA-farER. Assesses were
imaged daily and surface area was quantified using ImageJ. A. Abscess surface area at 2
days post-infection. B. The virulence exhibited by USA300ΔfakA was in a farERdependent manner consistently throughout the course of infection. The reduction in
virulence exhibited by USA300ΔfakA-farER is significant relative to that of
USA300ΔfakA as determined by a two-way ANOVA where *P < 0.05. Error bars
represent Standard Error of the Mean. n=8 abscesses per strain.
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3.4$ Discussion$$
This work provides the first mechanistic insight into the regulation of the RND family
efflux pump FarE, by the TFR FarR, which together function to confer resistance of S.
aureus to antimicrobial unsaturated free fatty acids. FarR, as with other TFRs, is autoregulatory in nature. The transcription of farE increases in response to linoleic and
arachidonic acids and gene fusions demonstrated that expression of farE is induced only
in the presence of functional FarR. This represents one of the very few TFRs with dual
functionality. 6×His-tagged FarR binds an operator overlapping the -10 element of PfarR,
upstream of the transcriptional start site of the gene, as well as another operator
downstream of the transcriptional start site. 6×His-tagged FarR also binds a third operator
upstream of PfarE. Taken together, our mobility shift and reporter-gene assays establish a
working model for us to further refine the mechanism by which farE is regulated by farR.
First, FarR binds to an operator site within OP13, which includes the -10 motif of PfarR,
leading to strong repression of FarR expression. An overlapping but independent operator
site within OP5 could potentially function to repress both farR and farE, while binding to
a third site in OP4 which is upstream of the predicted PfarE, is most likely to promote
activation of farE expression. For simplicity, we refer to OP13 and OP5 as OPRep and
OP4 as OPAct.
Reporter-gene assays show that FarR has a repressive effect on its own gene, independent
of the addition of fatty acid ligand, as evident from the low activity of farR::lux during
growth of USA300 in TSB. Consequently, during growth in TSB, our data indicate that
farR is strongly auto-repressed. Accordingly, the introduction of a single base pair
substitution in the -10 element of PfarR led to abolishment of FarR binding in mobility
shift experiments, and relief of auto-repression in reporter-gene assays. Similarly, a single
nucleotide polymorphism that resulted in a His121Tyr substitution in FarR displayed a
constitutive level of farE expression in the absence of a fatty acid inducer, concomitant
with increased resistance to linoleic acid, and less effective repression of farR. Therefore,
to identify the operator site responsible for auto-regulation, we looked for differential
binding between FarR and the FarR7 protein. Although OP5 partially overlaps with
OP13, it supported FarR7 binding, whereas OP13 did not, suggesting that the latter is the
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dedicated site for auto-repression. Although the location of this His121Tyr substitution
was not within the N-terminal DNA binding domain of FarR, our data suggest that it does
have a role in maintaining DNA-binding affinity. In a similar example, certain residues of
the C-terminal ligand domain of B. subtilis FadR undergo structural changes upon acylCoA binding, to affect the conformation of the DNA-binding domain. Mutations in these
residues resulted in lower DNA binding affinity (28).
Since 6×His-tagged FarR also binds OP5, it is feasible that OP5 is also a site for farE
repression. Typical repressors such as the prototypic TetR bind inverted repeats located
downstream or spanning the -10 element of their respective promoters (28), and OP5 is
located immediately downstream from the putative +1 transcription start site of farE.
Although binding to OP5 may not prevent RNA polymerase binding as anticipated of
typical transcriptional repressors, it would still obstruct transition of the transcription
complex, causing repression. Similarly, the staphylococcal QacR, a repressor of
multidrug efflux pump QacA, binds an inverted repeat located immediately downstream
of the qacA promoter. This operator also overlaps the transcription start site of qacA to
block the transition of the RNA polymerase-promoter complex that otherwise allows for
gene transcription (34, 35). Additionally, RutR, a TFR in E. coli, represses its own
expression by binding to an operator site located downstream of its transcription start site.
This binding mode seems to be indicative of negative regulation by either interfering with
open complex formation, elongation complex initiation, or RNA polymerase transition
(36, 37). Conversely, both FarR and FarR7 bind OP4, located upstream of PfarE, equally
well, and do not bind any other operators upstream of PfarE or within the 5#-end of the
divergent farR, suggesting that binding to OP4 would be most likely to activate farE.
Studies show that the activation of the acrAB promoter in E. coli is in response to
accumulation of cellular metabolites, and that global transcriptional activators (MarA and
SoxS) and a local TetR-transcriptional repressor (AcrR) regulate the RND-efflux pump
AcrB, to ensure that this pump is only expressed when needed. Binding of a wide range
of toxic compounds to the C-terminal ligand binding domain of AcrR results in a
conformational change in its N-terminal DNA binding domain, and this in turn releases
the protein from operator DNA and permits transcription. However, the inactivation of
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AcrR must also be accompanied by the induction of global regulators in order to achieve
acrAB expression (8, 7, 38). Consequently, relief of de-repression alone is insufficient to
promote constitutive expression of the AcrB efflux pump. In the context of FarE and
FarR, binding of FarR to both OPRep and OPAct may be a regulatory mechanism by which
FarR controls the expression of the farE efflux pump to ensure it is only expressed when
needed. We also examined all three operators that supported FarR binding and attempted
to identify any common sequence that may be a specificity determinant for protein
binding. There seems to be a clear preference for a common TAG(T/A)TTA binding
motif in all three operators; 5#GTGTAGTTTAAT3# in OP4, 5#GTGTAGATTATT3# in
OP5, and 5#TTATAGTTTAAA3# in OP13. We performed competition EMSAs with a
combination of mutations and deletions of these motifs and found that FarR discriminates
in favor of TAG nucleotides at positions 4, 5 and 6 of each binding motif. Interestingly,
analysis of multiple sequence alignment of 13 staphylococcal species that contain
divergent farER revealed that FarR binding motifs are conserved among these
staphylococci. Importantly, the TAG nucleotides located in the binding motifs of OP4,
OP5, and OP13 are highly conversed among these species (Fig. 3.8).
Structural studies will be needed to further shed light on the exact regulatory mechanism
of FarR and its mechanism of de-repression and farE activation. There have been reports
of TFRs with unconventional regulatory functions, such as RutR, that can both activate
and repress gene expression in its apo-form.

RutR is auto-regulatory, represses a

divergently transcribed gene, and activates yet a third promoter. The mechanism by
which RutR activates gene expression is yet to be determined, but the location of its
operator sites suggests a mechanism of de-repression rather than actual recruitment of
transcription machinery (36, 39). Another unconventional TFR is AmtR of
Mycobacterium smegmatis which is involved in a post transcriptional regulation of urea
metabolism without binding to any effector molecule. This regulation utilizes a sensory
system that involves a trans-acting sRNA in response to nitrogen availability. When
nitrogen is overabundant, the sRNA targets amtR mRNA and blocks its translation.
Under nitrogen starvation, the sRNA is down-regulated and amtR is successfully
translated. The AmtR repressor then works in combination with the global nitrogen
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activator, GlnR, to fine-tune the expression of urea-degrading metabolic pathway (40).
Another possibility is that FarR exhibits a regulatory network similar to that of DhaS, an
unconventional TFR from Lactococcus lactis that functions as an activator. Similar to
FarR, DhaS binds an operator site upstream of the Dha promoter, spanning the -35
element of the promoter. The mode of action of DhaS is not a direct de-repression, but
rather involves a transcription co-activator, DhaQ, that forms a complex with DhaS upon
ligand, dihydroxyacetone, binding and subsequently activates transcription of the
dihydroxyacetone operon (12).
Upon entry into the cell, exogenous fatty acids bind FakB, and after phosphorylation by
FakA, the resulting acyl-PO4 is incorporated into phospholipid directly, or alternately, the
PO4 is exchanged for a CoA moiety, and the fatty acid passes through an extension cycle
by the FASII machinery. A recent report by Lopez et al. has demonstrated that a Type
VII secretion system (T7SS), which is crucial for prolonged bacterial survival and
persistence of S. aureus in abscesses, is activated by uFFAs such as linoleic and
arachidonic acids. Additionally, this activation is contingent on the incorporation of
uFFAs into phospholipids and lipoprotein by the Fak machinery (41, 42). Therefore, the
similar virulence we observe in wildtype USA300 and USA300ΔfarER is perhaps due to
functional Fak machinery. Despite the evidence of a connection between farER and the
fatty acid kinase fakA in vitro and in vivo, a direct interaction between FarE, FarR and
FakA has yet to be demonstrated.! Here we show that USA300ΔfakA exhibits increased
constitutive levels of farE, but expression cannot be further induced by exogenous
linoleic acid. This mutant was also significantly more resistant to killing by bactericidal
concentrations of linoleic acid compared to wildtype USA300, and this phenotype was
farE-dependent. A recent report indicates that USA300ΔfakA exhibited an elevated pool
of intracellular fatty acids (43). Consequently, as reported in other RND efflux systems,
an increased pool of intracellular metabolites in USA300ΔfakA may be responsible for
increased basal expression of farE. Interestingly, FarR binding to OPRep was partially
reduced in the presence of linoleoyl-CoA and arachidonoyl-CoA (Fig. 3.13). Therefore,
perhaps the accumulation of intracellular fatty acids results in the fakA mutant
background leads to partial de-repression of farE, which cannot be fully induced due to
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the fatty acids being unable to be phosphorylated in the absence of fakA. As such, it
appears likely that phosphorylated fatty acids are the signal for regulation of farE via
farR. Experiments to test this would contribute to our understanding of the complex farRdependent activation of farE. Antimicrobial unsaturated fatty acids represent a vital
component of innate immunity, and S. aureus is constantly exposed to them, not only
during colonization but also in the context of an infection. It is evident that one of the
strategies S. aureus employs to cope with these fatty acids is via a complex regulatory
mechanism where a TFR with dual functionality controls the expression of a fatty acid
specific efflux pump. !
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Figure 3.13 FarR binding to OPRep is partially affected by linoleoyl-CoA and
arachidonoyl-CoA. In each EMSA reaction, 5 pmol of DNA is incubated with 0, 0.5 or
2 µM FarR in the presence or absence of 50 µM ligand, as indicated.
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4.1$ Summary$$
S. aureus USA300 is the current epidemic strain of CA-MRSA in North America. It
accounts for 98% of MRSA infections presented to emergency departments in the United
States. This strain is notorious for its ability to overproduce toxins and virulence factors,
as well as its remarkable ability to persist on skin surfaces. In order to persist on skin
surfaces, the bacterium must have intrinsic mechanisms to cope with the antimicrobial
uFFAs that constitutes an important component of the immune defense mechanisms on
the skin. These uFFAs are membrane-disruptive, and humans deficient in the production
of these fatty acids are more susceptible to S. aureus infections. The purpose of this thesis
was to better understand the genetic basis for S. aureus USA300 adaptation to uFFAs
which allows this strain to establish a successful infection. When USA300 variants were
selected for their ability to grow in elevated levels of uFFAs, two out of the seven clones
that were sent for whole genome sequencing contained a SNP in an uncharacterized gene,
SAUSA300_2490. Using domain enhanced lookup time accelerated BLAST, the amino
acid sequence of SAUSA300_2490 has 99% homology to TFRs. Furthermore, structure
prediction using homology modeling server, Phyre2, predicts that SAUSA300_2490
shares 99.8% amino acid sequence similarity with FadR, a TFR of fatty acid degradation
in T. thermophilus. Typically, TFRs exert their effects on divergent genes. Bioinformatics
revealed that the SAUSA300_2489 gene, which is divergently transcribed from
SAUSA300_2490, encodes a gene product that belongs to the Resistance-Nodulation-Cell
Division (RND) superfamily of proteins, which promote proton-antiport dependent efflux
mechanisms. The SAUSA300_2489 gene has an MMPL domain that codes for members
of putative integral transmembrane proteins that are linked with lipid-metabolizing
enzymes, suggesting a possible role in the efflux of fatty acids. As such, in chapter 2 my
aim was to characterize SAUSA300_2490 and its divergent gene, their role in fatty acid
resistance, and also characterize the effect of the SNP that lead to the identification of
these two genes. First, I show that resistance to antimicrobial uFFAs is inducible in S.
aureus. Second, SAUSA300_2490 which I named farR, for a regulator of fatty acid
resistance, is required for the inducible resistance to uFFAs. Third, SAUSA300_2489
which I named farE, for an effector of fatty acid resistance, is a contributor to S. aureus
persistence in the presence of antimicrobial uFFAs. Importantly, this farE-dependent
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persistence is not only in the hyper-virulent MRSA, but also in methicillin-susceptible
(MSSA) background. Furthermore, I show that FarE is an efflux pump in which its
inactivation results in elevated uptake of [12C]linoleic acid into bacterial cells. Fourth, I
show that a SNP that resulted in His121Tyr substitution in the regulator FarR is alone
sufficient to promote increased resistance to bactericidal levels of uFFAs. Unexpectedly,
the growth analyses and reporter-gene assays of this chapter show that FarR is required
for farE expression; a phenotype unusual for a typical TFRs. To follow up on this
phenotype, I constructed an in-frame, markerless deletion of both farR and farE to
conduct further studies on gene expression and structure-function relationships as I
utilized transposon insertions mutants in all analyses of chapter 2.
In chapter 3, my aim was to characterize FarR, its regulatory function and its operator
sites. First, using USA300ΔfarER I show that farE cannot be induced in the absence of
FarR, thus confirming that FarR is a TetR family activator. Second, I show that, unlike
the staphylococcal QacR, FarR is auto-regulatory by binding to an operator site spanning
its transcription start site. Third, I utilize electrophoretic mobility shift assays to examine
the binding of His-tagged recombinant FarR to DNA operators with varying lengths and
locations. I show that FarR utilizes three operator sites located in the farER intergenic
segment to exert its regulatory functions. One operator spans the -10 core promoter
element of PfarR as well as its transcription start site, and represents the site of autorepression of farR. Another operator that is located immediately downstream of the
predicted transcription start site of farE, and represents a potential site of repression of
both farR and farE. A third operator is located upstream of PfarE, and represents the
potential site of activation of farE. Interestingly, I also show that although the His121Tyr
substitution in FarR is not physically located within its N-terminal DNA binding domain,
it still affects DNA binding affinity and causes a relief to the auto-regulation. I also
examine whether the FarR-dependent regulation of the fatty acid efflux pump FarE is
linked to the mechanisms of fatty acid detoxification in S. aureus. It is established in the
literature that fatty acid kinase deficiency in S. aureus promotes hyper-virulence in
murine models of skin infection. I also show that this virulence is farE-dependent in vitro
and in vivo, and that fatty acid kinase deficient mutants exhibit elevated constitutive
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levels of farE that cannot be induced by exogenous fatty acids; an intriguing phenotype
that contributes to what is established in the literature regarding S. aureus pathogenesis.

4.2$ Limitations$and$future$studies$$
FarR is a novel TFR that functions as a repressor in the absence of a fatty acid inducer,
while acting as an activator in its presence. The transcription of farE increases in
response to linoleic and arachidonic acids, and gene fusions demonstrated that expression
of farE is induced only in the presence of functional FarR. Yet mobility shift assays show
that FarR binds with similar affinities to OPRep and OPAct. These findings raise two
questions that my studies could not address; first, what is the mechanism by which FarR
activates farE? And second, what is the ligand mediating this activation?
There are very limited reports of TFRs that exert positive-regulatory roles. DhaS, for
example, is an unconventional TFR that functions as an activator (1). It binds an operator
site upstream of the dha promoter, not to directly de-repress its target gene, but rather to
bind a transcriptional co-activator, DhaQ. DhaQ then forms a complex with DhaS and
subsequently activates transcription. In this situation, it is the transcriptional co-activator
DhaQ which binds the physiologic ligand, dihyroxyacetone. Consequently, the TFR
DhaS will only form a complex with the ligand-bound form of the transcriptional coactivator DhaQ (1). In consideration of this example, it is possible that FarR requires a
co-activator that is yet to be determined; potentially either FakA and/or FakB2.
Perhaps identification of the endogenous ligand of FarR can aid in determining the exact
mode of its regulation. TFRs typically bind hydrophobic ligands. Crystallography studies
of FadR of B. subtilis, for example, show that acyl-CoAs are often co-crystallized with
the protein from the E. coli host (2). Furthermore, FarR binding to OPRep is partially
reduced in the presence of linoleoyl-CoA and arachidonoyl-CoA; however, it cannot be
concluded that acyl-CoAs are the endogenous ligand for FarR. It is most likely that
phosphorylated fatty acids are the ligand modulating the binding of FarR to its operator
sites. A fakA-deficient mutant exhibit elevated constitutive levels of farE that cannot be
further induced, due to the fact that fatty acids cannot be phosphorylated in the absence of
this kinase. Purification of the fatty acid kinase proteins and the subsequent manual
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phosphorylation of fatty acids for the use in mobility shift assays can help in confirming
that phosphorylated fatty acids are the signal for regulation of farE via farR.
Additionally, work is in progress to express FarR with a C-terminal 6×His tag in S.
aureus. With this reagent in place, we could purify 6His-FarR from lysates of S. aureus
grown in presence or absence of linoleic acid, and then conduct mass spectrometry to
identify any protein or small molecule ligands that are captured in complex with FarR.
S. aureus can only synthesize branched- and straight-chain fatty acids as its genome does
not code for any membrane phospholipid desaturase for synthesis of unsaturated fatty
acids (3). Instead, the bacterium employs the fatty acid kinase (Fak) machinery to utilize
host-derived uFFA for incorporation into the otherwise energetically expensive
membrane lipid components (phospholipids, lipoproteins and cardiolipin) as well as
lipoteichoic acids (4–6). A recent report by Lopez et al. has demonstrated that a Type
VII secretion system (T7SS), which is crucial for prolonged bacterial survival and
persistence in abscesses, is activated by uFFAs such as linoleic and arachidonic acids (7).
Additionally, this activation is contingent on the incorporation of uFFAs into
phospholipids and lipoprotein by the Fak machinery. This incorporation and subsequent
stimulation of T7SS are required for virulence of S. aureus in a murine bacteremia model
(7). Our data also provide evidence of a connection between the efflux pump FarE and
fatty acid kinase FakA in vitro and in vivo. Since exogenous uFFA utilization by Fak
machinery is central for S. aureus virulence, tight transcriptional regulation is then
required to permit incorporation of uFFA into phospholipids, and induction of farE only
when the metabolic capacity for incorporation into phospholipid is exceeded. Therefore,
it is beneficial for the bacterium to fine tune the expression of farE such that it is induced
rapidly when the cellular threshold for uFFA incorporation into phospholipid is exceeded,
and subsequently represses the pump’s expression once the fatty acid concentration falls
below that threshold. This may explain the complex FarR-mediated regulatory
mechanism of FarE, to ensure that the efflux pump is only expressed when needed. This
also may explain the observation that FarR binds with similar affinities to OPRep and
OPAct as well as both FarR and the variant FarR7 bind equally well to OPAct. Perhaps
FarR binds constitutively to OPAct but the binding to OPRep is what modulates the tight
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regulation of farE expression. Therefore, in the absence of inducing ligand, binding to
OPRep can repress farE and in the presence of inducing ligand, binding to OPRep is
reduced, and binding to OPAct can then contribute to activation of farE (Fig. 4.1). Further,
analysis of the putative farE promoter reveals a GC-rich spacer between the predicted -10
and -35 promoter elements. This spacer, as opposed to a more typical AT-rich spacer in
strong promoters, is indicative of reduced promoter activity that requires a transcriptional
activator to help recruit RNA polymerase and the transcription machinery (8), further
supporting the requirement for FarR as an activator of farE.
Reporter-gene assays show that FarR auto-represses its own expression, independent of
the addition of fatty acid ligand. This raises the question as to why farR expression
cannot be de-repressed in the presence of fatty acid inducer, while farE expression is derepressed. Perhaps FarR does not directly require ligand binding, but rather employs a
more complex regulatory mechanism that senses the fatty acid pool in the cell. The TFR
AmtR, for instance, is involved in a post-transcriptional regulation of urea metabolism
without binding to any effector molecule (9). This regulation utilizes a sensory system
that involves a trans-acting sRNA in response to nitrogen availability. When nitrogen is
overabundant, the sRNA targets amtR mRNA and blocks its translation. Under nitrogen
starvation the sRNA is down-regulated and amtR is successfully translated. The AmtR
repressor then works in combination with the global nitrogen activator, GlnR, to fine-tune
the expression of urea-degrading metabolic pathway (9). Additionally, LuxR of V.
harveyi that deviates from the norm of TFRs and functions as both repressor and activator
depending on the presence or absence of a modulating ligand, is also subject to sRNAmediated regulation to ensure tight post-transcriptional control of quorum sensing genes
(10). Small RNAs can be encoded on the opposite strand of target mRNA, and despite the
complementarity, they block translation. These antisense RNA molecules often target 5#
untranslated regions (UTR) that are close to or overlapping the ribosomal binding site of
target genes (11–13). Therefore, it is possible that FarR employs tight post-transcriptional
regulatory mechanism to ensure that the efflux pump is only expressed when needed. Not
only the spatial arrangement of PfarR and PfarE on the plus and the minus strands conform
to the typical antisense and target mRNA paradigm, but also analysis of putative PfarE did
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reveal a 5#-UTR, upstream of the ribosomal binding site of farE, that is indicative of posttranscriptional regulation (Fig. 4.2). Further, analysis of PfarR revealed an even longer 5#UTR, compared to that of farE, that also suggests a possible post-transcriptional
regulation of farR (Fig. 4.2). Structural and functional studies will be needed to further
shed light on the exact regulatory mechanism of FarR and its mechanism of de-repression
and farE activation.
In conclusion, this thesis reports the first description of a specific mechanism of inducible
resistance to antimicrobial fatty acids in a Gram-positive pathogen, and the first
staphylococcal TFR that functions as an activator and a repressor. It is evident that one
of the strategies S. aureus employs to cope with antimicrobial fatty acids and persist
successfully on a human host is via a complex regulatory mechanism where a TFR with
dual functionality controls the expression of a fatty acid specific- efflux pump.
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Figure 4.1 Schematic model of the potential mechanism of PfarE regulation by FarR,
depending on exogenous fatty acid ligand. FarR binds constitutively to OPAct but the
binding to OPRep is what modulates the regulation of farE expression. A. In the absence
of inducing ligand, FarR binds to OPRep, thereby blocking transcription from PfarE. B. In
the presence of inducing ligand, binding to OPRep is reduced, and binding to OPAct can
then lead to activation of farE.
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Figure 4.2 Secondary structure prediction of farE and farR RNA using RNAfold
Webserver. The nucleotides are colored according to the type of structure that they are
in. A. farE. B. farR.
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Appendix 2. Adaptation of S. aureus USA300 during growth in TSB + 50 µM
linoleic acid. A. Cells from overnight culture grown in TSB were inoculated into TSB +
50 µM linoleic acid, to achieve OD600 = 0.01. B. Cells from stationary phase of the
primary culture were inoculated into fresh TSB + 50 µM linoleic acid
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Appendix 3. Differential effect of pGYlux and pGYfarE::lux on growth of S. aureus
USA300 in TSB + 20 µM linoleic acid.

Triplicate flasks of USA300 harboring

pGYfarE:lux, or empty pGYlux vector were inoculated into TSB + 20 µM linoleic acid,
and growth (OD600) was monitored on an hourly basis.
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Appendix 4. Exponential phase cells are highly susceptible to the bactericidal
activity of 100 µM linoleic acid (LA). USA300 cells from an overnight culture
(stationary phase) or mid-exponential phase culture (OD600 = 0.5) were inoculated to
achieve OD600 = 0.01, in TSB containing 100 µM LA, and viability was monitored at
hourly intervals. Each data point represents the mean and standard deviation of triplicate
cultures.
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Appendix 5. Cadmium inducible expression of farR protects USA300farR::ΦΝΕ
from the bactericidal activity of 100 µM linoleic acid. For challenge without Cd,
USA300farR::ΦΝΕ + pCNfarR was grown to mid-exponential phase in TSB + 20 µM
linoleic acid, and then sub-cultured to OD600 = 0.01 in TSB + 100 µM linoleic acid,
followed by monitoring of viability at hourly intervals. To induce farR expression,
USA300farR::ΦΝΕ + pCNfarR was grown to mid-exponential phase in TSB + 20 µM
linoleic acid and 10 µM Cd, followed by subculture into TSB + 100 µM linoleic acid and
10 µM Cd. Each data point represents the mean and standard deviation of quadruplicate
flasks. Significant differences in viability at each time point were determined by unpaired
one-tailed Student’s t-test; ***, P < .001; **, P < 0.01; *, P < 0.05
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Appendix 6. FAR7, but not USA300, is able to grow in TSB containing 50 µM
palmitoleic acid (PA). Stationary phase cells of USA300 or FAR7 were inoculated into
TSB containing 50 or 100 µM palmitoleic acid, and growth (OD600) was monitored at
hourly intervals. Each data point represents the mean and standard deviation of triplicate
cultures.
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Appendix 7. fakA-farER influence virulence in a murine skin abscess model of
infection. 6-week female BALB/c mice were infected with 2x107 CFU of USA300,
USA300ΔfarER, USA300ΔfakA and USA300ΔfakA-farER. Assesses were imaged daily
and surface area was quantified using ImageJ. The reduction in virulence exhibited by
USA300ΔfakA-farER is significant relative to that of USA300ΔfakA as determined by a
two-way ANOVA where *P < 0.05. Error bars represent Standard Error of the Mean. n=8
abscesses per strain.
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Appendix 8. Purification of 6×His-tagged FarR from wildtype USA300 and the
variant FAR7 using nickel affinity chromatography. Cell lysate was applied onto a 1
mL His-Trap nickel affinity column that was equilibrated with binding buffer (20 mM
sodium phosphate, 0.5 M NaCl, 40 mM imidazole, pH 7.4). After washing with binding
buffer, bound His-tagged protein was eluted over a linear imidazole gradient (0.1-0.5 M)
in 20 mM sodium phosphate. Column fractions were assessed by SDS-polyacrylamide
gel electrophoresis to check for purity. L is the unbound fraction from the column, and
W is the washed flow through fraction. Purified FarR protein band is at ~ 23 kDa. A.
Native FarR and B. Variant FarR7.
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